var title_f3_61_4048="Ring pessary in situ";
var content_f3_61_4048=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Ring vaginal pessary in situ",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_61_4048=[""].join("\n");
var outline_f3_61_4048=null;
var title_f3_61_4049="Modified Allen test";
var content_f3_61_4049=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Modified Allen test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient's hand is initially held high while the fist is clenched and both radial and ulnar arteries are compressed (A); this allows the blood to drain from the hand. The hand is then lowered (B) and the fist is opened (C). After pressure is released over the ulnar artery (D), color should return to the hand within six seconds, indicating a patent ulnar artery and an intact superficial palmar arch.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from American Heart Association. Textbook of Advanced Cardiac Life Support, 1994.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_61_4049=[""].join("\n");
var outline_f3_61_4049=null;
var title_f3_61_4050="Cutis marmorata - legs";
var content_f3_61_4050=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F50846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F50846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cutis marmorata",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A net-like, violaceous pattern is visible on the legs of this infant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_61_4050=[""].join("\n");
var outline_f3_61_4050=null;
var title_f3_61_4051="Left hemidiaph paralysis";
var content_f3_61_4051=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left hemidiaphragm paralysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 373px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bartolome Celli, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_61_4051=[""].join("\n");
var outline_f3_61_4051=null;
var title_f3_61_4052="Erythromycin (ophthalmic): Patient drug information";
var content_f3_61_4052=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Erythromycin (ophthalmic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26419?source=see_link\">",
"     see \"Erythromycin (ophthalmic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/41/42642?source=see_link\">",
"     see \"Erythromycin (ophthalmic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F11426064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ilotycin&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8086247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Diomycin&reg;;",
"     </li>",
"     <li>",
"      PMS-Erythromycin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10031069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691501",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat eye infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10031068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702046",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to erythromycin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10031073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10031074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10031076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10031071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695513",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place drug inside the lower lid. Close the eye for 1 to 2 minutes. Roll eyeball around.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695617",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 10 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10031072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10031077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10031078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11671 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-E57427EB1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_61_4052=[""].join("\n");
var outline_f3_61_4052=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11426064\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086247\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031069\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031068\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031073\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031074\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031076\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031071\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031072\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031077\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031078\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26419?source=related_link\">",
"      Erythromycin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/41/42642?source=related_link\">",
"      Erythromycin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/6/25705?source=related_link\">",
"      Erythromycin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/23/22901?source=related_link\">",
"      Erythromycin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/32/22025?source=related_link\">",
"      Erythromycin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/28/31171?source=related_link\">",
"      Erythromycin (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/47/756?source=related_link\">",
"      Erythromycin (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/6/30818?source=related_link\">",
"      Erythromycin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_61_4053="Carbinoxamine: Patient drug information";
var content_f3_61_4053=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Carbinoxamine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/8/11398?source=see_link\">",
"     see \"Carbinoxamine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/5/37972?source=see_link\">",
"     see \"Carbinoxamine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F145677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Arbinoxa&trade;;",
"     </li>",
"     <li>",
"      Palgic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before giving this drug to a child. Check all of your child's drugs, including OTC, with doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691896",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hives.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat swelling of the face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to carbinoxamine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697164",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bowel block, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697349",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have trouble passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is most useful if started before contact with the allergen. Take at least 1 to 3 hours before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695884",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11596 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-D795AC79FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_61_4053=[""].join("\n");
var outline_f3_61_4053=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145677\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018331\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018333\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018332\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018337\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018338\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018340\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018335\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018336\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018341\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018342\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/8/11398?source=related_link\">",
"      Carbinoxamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/5/37972?source=related_link\">",
"      Carbinoxamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_61_4054="Malignant perivascular nodules";
var content_f3_61_4054=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75183%7EPULM%2F53000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75183%7EPULM%2F53000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Perivascular nodules",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 241px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADxAXsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5+8VeIdaTxPrCprGoqq3kwAFy4AG8+9Zf/CSa5/0GdS/8Cn/xo8Wf8jVrP/X7N/6Ga3fAYzDP05f09hQBhf8ACSa5/wBBnUv/AAKf/Gj/AISTXP8AoM6l/wCBT/416cB8p4yPQ1fmIt7aOAcM/wA8h/kKAPIv+Ek1z/oM6l/4FP8A40f8JJrn/QZ1L/wKf/GvXoLZpF3EmNPUnr9KmnIleOGAERIMLnv6mnYDxv8A4STXP+gzqX/gU/8AjR/wkmuf9BnUv/Ap/wDGvbSqrGrPnyk+VF7se5pba2utUuVitbeSZ2OFVBnFFgPEf+Ek1z/oM6l/4FP/AI0f8JJrn/QZ1L/wKf8Axr7G8KfBea4EVx4hujGh+YwRcN9Ca9g0Dw3pWgwCLS7SOLHBYD5j9TSA/Nn/AISTXP8AoM6l/wCBT/40f8JJrn/QZ1L/AMCn/wAa/T0dMCl+tAH5g/8ACSa5/wBBnUv/AAKf/Gj/AISTXP8AoM6l/wCBT/41+n2KKAPzB/4STXP+gzqX/gU/+NH/AAkmuf8AQZ1L/wACn/xr9PQMAAZ/E5paAPzB/wCEk1z/AKDOpf8AgU/+NH/CSa5/0GdS/wDAp/8AGv0+ooA/MH/hJNc/6DOpf+BT/wCNH/CSa5/0GdS/8Cn/AMa/T7vRQB+YP/CSa5/0GdS/8Cn/AMaP+Ek1z/oM6l/4FP8A41+n1FAH5g/8JJrn/QZ1L/wKf/Gj/hJNc/6DOpf+BT/41+n1FAH5g/8ACSa5/wBBnUv/AAKf/Gj/AISTXP8AoM6l/wCBT/41+n1FAH5g/wDCSa5/0GdS/wDAp/8AGj/hJNc/6DOpf+BT/wCNfp9RQB+YP/CSa5/0GdS/8Cn/AMaP+Ek1z/oM6l/4FP8A41+n1FAH5g/8JJrn/QZ1L/wKf/Gj/hJNc/6DOpf+BT/41+n1FAH5g/8ACSa5/wBBnUv/AAKf/Gj/AISTXP8AoM6l/wCBT/41+n1GBnOOaAPzB/4STXP+gzqX/gU/+NH/AAkmuf8AQZ1L/wACn/xr9PqKAPzB/wCEk1z/AKDOpf8AgU/+NH/CSa5/0GdS/wDAp/8AGv0+OCCCOKwNc8JaRrMbC6tU3H+NRgigD84P+Ek1z/oM6l/4FP8A40f8JJrn/QZ1L/wKf/GvsLxj8G5Ig82kESoOQp6ivHNW0O/0y4aO7gkUjI6Yp2A8g/4STXP+gzqX/gU/+NH/AAkmuf8AQZ1L/wACn/xr0l12tgkLkfU4qHbufBcsRzyRg/WiwHnn/CSa5/0GdS/8Cn/xo/4STXP+gzqX/gU/+NehSZVS8SZIHCooBJ9MntULRFWAc43HoSOc0WA4P/hJNc/6DOpf+BT/AONH/CSa5/0GdS/8Cn/xr0S7G+xgTp5Y2qQvb29qyNSSaOLc4aQds0gOS/4STXP+gzqX/gU/+Ne8fDLVtSm8Eaa8uoXjufNyzTsSf3r98185yHLsfUmvfvhb/wAiJpn/AG1/9GvQB4r4s/5GrWf+v2b/ANDNb/gLb9mnB258zjPXoKwPFn/I1az/ANfs3/oZrofAOPslwGBIMnTHHQUAdvZQiSX5ztjQbmJqaNhNM00ihueE7VObeO0skWdmEk3zFF5OOwPpSJAq7JImJhfjkdCOxpgMnaWVxuyewXsKsWlnHayyOAouJgC+OwAxk++KtWgklmSCzhLzucKEGSa9k8CfCceWl34jxg4YW6nr/vUCPOfCfgrVfFl1GLaBo7BGAMzghcd+a+ivCvhLTfDdsiWsStMBzIV5/Ct21tobS3SC1iSKFBhVQYAqYDFIYnJ9qXFFFACFcsDkjHb1paKKACiiobm6htk3TOFH60ATUEgDJIArmr/xRDCGKlVQfxMeT+Fcdf8Aju2MkitcMxHYHgU7AelXN/FCDt+dh2FZd1r4hAYABD3ryS48dzSFxDEz44z0/Gsi/wDFl/MVjYptAwEU9/eiwj2v/hK7dSxdhgdu9W4fEds9uZXGB2wa+cm1a5eUmWYhFOCRWhN4juBbiKEkhRRYD3uTxRp8Ue5357AGlXxLZmJXBJB46ivnK51KecpJNMwBYKAvb3pXv7xZG8m6d0JwA3GaLAfTVvq1pNj96Ez03HGavKwYAqQQehFfLceu6nAhZbgugOMH+ldBo/xC1Cw24RnA5OG4I75FFgPoWgkAZJwK86m+IiXPhkX9gg84PskXunHXFcDqXxA1C+XHniP0Dnr/AIUWGe/faYd4XzY9xOANwqrqWorZo3yksBmvnCXxDrSv5qTqGB4I5H506fxlrF1EkF1cu+P4gev40WEe5Q+MbViQ+OOuO1XpfElmsSyKwKsM9a+bV1a7W5mAkdA/b1Nbba3PJYqu1ndeODwKLAe2T+L7SLHKE4zjdUC+N7QvyBtzg8nNeEpqV0wkZW3KnBBNRi/lyWEoHONueadgPpqy1Wzvf9RMpb0JwavV816Trl3a5CT5GecnkV3vhvx/IjiK8JkUDgk0rAer0Vl6ZrlnqEaNHIoLdATWp16UhhRiiigArnvE3hLSvENu0d5AqyH/AJaKMGuhoxQB8ufEL4VanoYe4sla7tP7ynkD3rzFI2ErK4Kt3G08V93SRrLGySqGRhggjg15b8QvhRZ6wj3mjAQXo52dFY0wPmST5F2rHubI6nHFQNcr83y7QuQTtJIP+FdL4o8OXuk3AW5gMeDtcFeQfWue8jDK75wp6f3v8aAELYxJKSo7bmxmsnUb+RIyEVR16rmrV3IWJbKhR8vByR/hWZqEZMR42qBwQvb8aAOBlYtK7HqSSa99+Fv/ACImmf8AbX/0a9eAv99vrXv3wt/5ETTP+2v/AKNekB4r4s/5GrWf+v2b/wBDNdT8N3jitLiQqXmWX5QR8o4HJrlvFn/I1az/ANfs3/oZrrPhjD59vcjhEEmWkJ4AwKAO0uQzzgucuyhia3tB0i91cRWGmQPNLI+SyjhfUmotB0uXxBrcVjpsLzTSEAv2VR3NfUXgrwrZ+F9PEVuqtcuB5suOvt9KYjM8AeANO8KW4kKi41GQAvM4yVPotdrj1pelFIYUUUUAFFFFABVe8vIbSMvO4Ue5rH8TeJLXRrZ2eUBwOfavGPE3jK71GVjCWMWO56+9OwHpfiDx5BaKVtiC3qOTXm+u+N727vHW1cmMHhj/ABVyLSCUN5rSCfsfao4olZWCyHKct64p2EW7i/u9QmaW5nYJz8ucCqy5m8xnz5mMhgOtK5X7OnzNtIwRSNvWO3O7aB0OOtACwtHGplfLOQApHAH1p10IWcNbqVfAO09D64pQhKM0ahmDAkfw4qewSJ7y4tpkMski5iKclW/woAP3MMMogXz47hBlsfNGfQVHBBPcboowW2Jvb5eg9TVr7BeJNGrpHCc5znCgDvR5E8MlztvImabAZkbgjPSgDPWWMW+xAvorkdPaleOWWyW5ZgwRtoI6g1fjsTbiWO6IMJPmKg5IxVGSSAgjL5U/KvY5oArLCVtwzzBV3Va8wP5bWaNkDa+Fzx6mop2HmhrZc44aOUcZ9qbBePamSSI+Vu4dByFFAHUeFbSe51Ge000id5k3HaPu+oIrnbpnju54JreNirlScYx9a9Z+BvhyS3gutfuwQ92PLtwRj92OS34n+VQ/FTwZbWrHXbLcoLYnh6qc9xRcDyFjKWcRIUX+Ijp+FOCWxmUzrL5RAH7sfeHtRd5zJsWUqDgMOwojb5oyzGPy1xk8ZagB8kcRX5IZFaM7dsrYYL2NWrC4jaCZJLZwcriZDgDnuKphbi8m/flpXfo+eDj3qe8E8QFtEjqjfPnsT6UAR3sASeQTO8coO/5QduO1UbjcpBDb0I5I7+9bcTzyxmWVjK4TyxEE5Hufaq1wbN7e1gitXhj6Gbs3r+FAGYlzJHOiyI4SXoQP51ctrhkuCksu0gZG4cfnSalMQVCjbEBtB65HrT5J2uLGzUokkcRIDFcfgTQBuaZ4lezlChzwBwDkYr0zwv44XyCLiViq42qeh/GvDn+VkcRbA44x/EPar90TDbW9xaOzHAEwUfKD2oA+pdN1CDULdZYGByOV7irlfOnh3xVd6ZLGk8hDjHQ5Fe2eGvEMOrWqksvmAc+9JoZv0UA5FFIAoxRRQBh+KPDGneJLJoL+EbiMLIv3lr5m+I3gC98L3jF1L2THKTAZH4+lfWtVdRsbbUbSS1voUmgkGGVhmgD4RmjdJcDIHXgYzWPqKFlZcKvGQM5I+te3/Fn4bS+GZXvrNHn0Vz9/q1uT2Pt7145qkbKp6FSvDAcEeuaYHmMn+sb6mvfvhb/yImmf9tf/AEa9eBTDErj/AGjXvvwt/wCRE0z/ALa/+jXpAeK+LP8AkatZ/wCv2b/0M12Xwv3PYywLG0rT3HlqqH5icL0rjfFn/I1az/1+zf8AoZr6J/Y38Lxaib/W7sB0sbgpEpGf3hVTn8BigD3v4V+C4fCujiSWP/iY3ADSFhyg/u13QGKKKACiikVg2cHocUALRRTZHWNCzkBR3NAA7BFJbpXG+MvF8GlWxSJ/3x4wKh8WeNIdNLCELIRx1rxjxHrE2t6hNd3G1V6BV7CmkIXV9Zmv7p2nZ3VuCW6L9azgrA43fus7SR2/CpICVgVk2SLKfLxQD9muY1mjJb7oP93FMBGt9zlI8bt2Fbsar3uYrwFIxHHkc+o71rx6ZfzoGiZJI8mVUPG71qC8iUlLYq+c5OedpoAjmVZZkigClzyD2zUUqTtb4kG5YmIb0z7VJFZyPNNHvSMRruDMcVsS2F7p3hKxklaIpdTFsZ5IoAxLclFjjUqsJOHY9h61JExsdRLWgYyRNkSDoy+1WEeS5tZbWNIwkudzEfdx71WkbaLORXyYjggdDigA1bUZ9QuAZ/kixlYgMEetaehaVHqMck1ywXS7f/WPjaS3YD1pNJtDrmqyJsZvlJ4OP1qz4jbFmmmabKYxbHc8X980AZ91M6S3Nraofsr8hs5fFZtwmxiJFwcdQMVJI06SQuqMjIOR3J9TU+oTCaUy4ZyVAy3GKAM+XY77yrKAADj+Zrf+HnhOTxZriCRGOk2zBrmU8B/RAfU1X8I+HtQ8UaqtvYLshXie4I+VF/qa+j9A0ez0LS4bDT4hHDGOw5Zu7H3NJgXoo0hiSKJQkaKFVQMAAdAKratYR6np81pP/q5FIPHQ9jVyikM+ZvFGkXHhvWbi2YEttypHRge9ZlvM8sb/AGq2juIjhQXG0D6V9DeNPCNn4mt1MhMV5ED5cq/yPqK8H1vSbrTLs2usq0ZQkIyj5TjpVCMaKCYByzqEVj5aKelXbbWWLQC5GxUO3cADn606400fYjNbXS+QE3MM8g+1ZlrZzTxebahbhUG91JwV/wAaAOjvBd23n3NukYd0zGqclqz9a+13FtYy3tk1uwGxyBhee+K0/D8QvrdA8pssAsGY53D1FZHn3DXE1vcXrzWZYrluSfQigCpbRNNcmGWUC1B+VwOh7UpuphHNChJyMCLZgH3q9o0c9m007Rf6K5KDzOMn1+lQTujTSmdv9JDfJLGPlX0oAoyyG5kj325KomAwyPL+ooFxize2RcwcNlT99s96lluJxOjS3Cr5vys5GAw9xUtwttDa3UMK+fcZGyZThQO+KAGXEMrOWtEdXBVXQnoD6VpeHdavNMvQiPJuVsbRntWLamBn33c00W1OH65PYUtv9uSXz7fcTjls549aAPpDwh4sttWgVZXCTdME9a60EEZHSvlnS9QutLuIGmheKVzvV88MK908C+Ko9Wt0hmOJwMcnrSsB2VFFFIYUUUUARXVvDdW8lvcxrLBKpV0cZBB7V8n/ABk8CN4NvndEeTw9dtiKUdYGP8B9vSvrWsrxPoln4i0K80rUYllt7iMoQwzg9iPegD8x72MRXk8YYMFdgCO/PWvefhb/AMiJpn/bX/0a9eNeMtGl8P8AiO+0yckvbTSRhic7grsAc++K9l+Fv/IiaZ/21/8ARr0AeK+LP+Rq1n/r9m/9DNfWP7EpJ8Da6M8DUc4/7ZJXyd4s/wCRq1n/AK/Zv/QzX1j+xKP+KH14/wDUR9f+mSUAfRtFFFAB6c0UUjMFUljgCgAYhVLMQABkk15f498aoha3ts+UOOOrmrvxN8VrYaeLa3cCSXqO4HvXilw006ec8obLYwx5ppCH6tfPeTNJKflPRc1HCEjl8xFE4x84Ixj1/Cqzxs8Zxsbbztz0NXrawuXhjuIgEjJ2kk9eKYDLt4BObm2/cL2j9T60s8xOniZJzJMsm0qV/UmrNtc20cUsawJKyt+8Vu30pRHbfaFebNtBONw5yregoAtXInW2hSK+Csq73Xp+ANJot6b26uLS5XaCCyO4GVrOminkuHe4Jbaf3YUY3LUun3sFrezXdxA4mXO2MdD70AXJg4WOO5jRvLfeMdZFHY1Y1W7luUE/kpHZgbViPVfoKzo3jMi3EUsjufmZW6f8Bq9rAiNlBcx7kJ+TZjjJoAzpb24kWOEqqRKODjls0trbS3KPEQi55Uj+96UxQ0dmrFmLq3KMMACr+lrBM9osKOLpW3nLcMtAGnYaTc6ZYXF1EFNw+E+Vun0rm5ZZUlSRyzTxktnH866PzJ31Hy5bspZ7yWDfc/OsjWLiE3ri3hXyMgM+ep9aAKd3JLciSaUEPj5gDwwrY8E+FbvxfdBbdmt9LiIE9wRnP+ynvV/wF4KHim/lmNzINEgkAk7NK3UoD6epr3uws7bT7SK1soI4LeIbUjjXAApNgRaPpdpo9hFZ6fCsUEYwAOp9ye5q7RRSGFBoooAK5zxholrq9mTdQl/LUkMOoro6iuiot5CwyApOKAPmO+sY4NVeO3HnRIck+vtUZhgmvxGjrbDpsU/ezUniUuuu3Jg81EcsGCcmmS2As4opFuA0TrtZ+rg+lUIZPaNDqDxxSgMiYTB+U1kK88EU1uY43eYcufvKc9qvLJcW86xxqZIFO0CUZGT61o6lo0sk8UsMexpBgMnKk98UAA/4mVpb2REskpUeW+7oQOhqtfWf2SxPmh1lUbSyDKk+ntWtcNa6XYWq2KFJt5E8jH7xPpVS9juotPnmO5I5ztABzn3NAGLb+bKVkuE+0Rj5WDD5RVuKBZJ7uS/RLaziXCCMZBNP0udYdNmtXkDtcdQB938aW0kSOBYXzLHnY6buFPv7UAUbNFn0+NVgZrd5cNPnJx9KmntlgvoY7CQyWPSVy2MjvxTEhDSywodkTH92IjgA1FaENPHDcQnyUYlxnkn1oAgv5WVxFiYQoSIWk6Yz2rX8PatPp95Fhisic9Ooqtrl6bmIRvIywRvtj2jLZ7Cqcc0T+bbTCYXbIMM/c0AfTXgvxBDrenhQQLiIAMvqPUV0dfM3gXxPLoes2zSOCmdp29x6V9J2dzHd2kNxAd0cqhlPsaTGTUUUUgCiiigD86fjcCPiBfgnJ3yc/wDbaSvQvhb/AMiJpn/bX/0a9ef/AByGPiFf8j78vT/rtJXoHwt/5ETTP+2v/o16APFfFn/I1az/ANfs3/oZr6v/AGJXH/CFa+ueRqAPX/pmlfKHiz/katZ/6/Zv/QzX1Z+xN/yJ+vn/AKfx/wCi1oA+kqKBxRQAjEKCScCub8Sa5HY27yMw2oM4PSl8R60bbdHCRlR8xz0rxfxnrsl4wg3/ACOSDjvTSEY2valNq+pXF3cKVMxyvPb6VQDWwlXzEKAHLlBwaJIWYorTKxx8uOdvsa1LjRsWLzCRgxUMR2PtTAopaK9yvzhbNycSAdfaqst01rNJBbTMVDbkOc4H/wCvNXtIgkWZoppI7ddu9RI3FTXenqto0+lqlwc4ODyD3x7UATW88VwqfaLZftc/DSD5QR9KammvczmE3GI1yFJGVB9qlvEkjtLV7kA3Eg/dMo4HsfSr1xDBbravNKpDoWKq2QGHU0AR6fAsc4TUbj5IxtHbBqGUST6hJbFEKAEq6DIHsferUmpWNxNDO0kTJtxKjry3uKkn1O3e6uLm1EdpbOBHtA5Y+oFAGbbWrTSrstg9mi7VBO35vXFRzyiFRa3e542bkDqvuK17nUbmOaBIvLlSGPasZGCPesq9lOpyos9vtufvPtGMAdsUAaOoaWbbw/FLYg3TTPwx5O0dqhspJbCOZ55PKCphhswfcCrvhrVpNCIR7XztOuGLMxO7y89c+lO8T6raTaayafAGG4bWJzkegoAz0BhtjLZ3Hnlz/qW5xWTd3EcgOVMdxINqqnRW9avcW+gyG7tZYZriQeSzZBHqaSMQTx+XBEqJbne7s3zSfSgD6A8D2UOn+E9Lt7ZAiCBSeOrEZJPvmtwHPavPfCXiGWPR7SIHeRxtbqBXbWN6LkcjBPOKkZcooooAKKKKADvmorqPzbd0PcYqWigD578d6bDYavNKZ5EmV8qgXhq5dzBdcMZIGAJdeqt6V6z8VtHB2XXks47lBmvNojezxpDMUt4gCEJXlx7mqEVfsaXGniVpvLkU4MR/iHbirtvMIdIitpppJbfzQd0ZwU9ah1Gzl+x26ptmZWOJYzkt7Gs+3m8i4NpLMY45M7tvIB96ANTVbmC+lFpZmSN05Uv1daisLG/1hl04mWVAu9wh5i9yaZFaIjRyzW0n2deDOn3vrXp3gbV9G07w7qEsQAmc9H++/GBQB5hei0sI5LGxi86eIjcG+9nvk1kW9xcbp2CLCGP3SMjFbmtWkEFxNdySSRT3TF1VOeKbbo/+jm5YXcZXcYwNrY96AMOEHz/Pil2GPkt/CT6CrE9+slxBJcRKYG4coetLeRm4nuSBFawofkV+uPpVuCy02XRLTzJ2cCb98yjGB70AR3U2my+ZDZJKGQBwf9qob65ubx4kkRFMeHdl+8fxqeaw8lrmSy8qSGMcFX6g96zJkkjCGaVUU8g5yT+NABN/pEiRxhUK85x1/GvYfgh4kYiXQLyXcYhvtyxyQP7tePxSj7G7opF4pwpHO9T/ACqzpd+dL1mx1CyLKYmG8A0AfWtFZ2hanHqdhFMuA7KCRmtGpGFFFFAH52/HZGT4iX4cgnfIeDn/AJbSV33wt/5ETTP+2v8A6NeuB+OoA+Id/gYXdJj/AL/SV33wt/5ETTP+2v8A6NegDxXxZ/yNWs/9fs3/AKGa+qv2JVJ8J6+247RfAbexPlryf8+tfKviz/katZ/6/Zv/AEM19WfsSY/4RDxD0yL5f/Ra0AfSVVNWulstOnnY/cXj61brk/iTc+Tokce4IJZACT7c0AeUeKdcae7lw5AI5Ga4ydvNffOuQehU9Ku3gN1fyRyEKGztOePrVDyjJlEw8sZxtHeqENgJtZzIoHlsChLehqVGMaLDe3TtBtJRAclfTNNmt5I1QE7nP8Lfwmi9sk3JlCs2OT13UAJIzu0bTIZFQ4DZ7dqueeLSMwwSKCW+Zk681W04Rrdq0+8W4yGOcgN2qayMU95NFdExxEkq2zGaAOg1a9tra1WCCMTzIoMj7sgjHX2PvVO3tRf6Ci2SO1yjFvK6sPaqaW8YmQPHKI9u55EBIx7+tWYtRXTdWjn0+YqseMOV++PQ0AM+z2RsbHYrNeyOVkgI+YGti6urW3EOmR6eskkbiWSVh830qC7WO51OK7UtG07bvMC5VT7H/HFMvUWVZ1guHklJyCVwW9eaAINcvNmpSXMECqm0LgNyMVZkt9RewXV7nMIZdokAyMfSsWNJIb6GS6wUX7xJzkehrpb++ivrNLa2mIw4OAeg9MUAc7FOlgXU3D3EMxG+MD71b9nZ6Faajpcl7LcmLzRJ9lTHOPXmqjafHBqELNGJGRxv8odAehNVL05vL+XUbWQjfsEh+XaOxFAHffFHWdF1ewtdkbO0JJUj5WHtj0rzaKa3eRP3flhsbCOT+VNPluES7mf7OpJUgfMfr7VJbTRiZogT5PXKgbvpmgDuPC0c6AFmBD9DnoK9S0QFI0JyTXkfhSUG1VS+Hycg9RXqnhm6S7SNFyWUZJ9qTA6akY4xyPxNYnifxFaaFbr58iieQfInf61xlr44sbi5AknIkY/x0rDPT6KzNIvI7q3WSKQOvQ4NadABRRRQBz/jm1mu/Dt0luGZwhOF6/hXz7ABNGls7M8obasjE/u/XjvX09ckrCzDqK8H8W28cOt3f2a0iy/zKQ+1g3sKaEUp9KvbG1ZYdl1CoyccY96xre1VommmkjitpQQQTkh/Y1du11SC3SWSUyMoxsQ9R6EVlW4ime4t50EUZ/eqozw1MDpEuN/hh7N7pRHkAsB8yr7CubaY22qRx20wnRflyRjHvTkuRI0qxQNcnYMbei1HeIYNLt5hCsSFtjSE/MzegFAHQ/2XNbLHfX0W9VXO6RvvZ9BWTfak51eNrJUMpTy3DcDB9K37vw7I/h+O9uL+WRo1HlxE/Liues7dG1KO3vZ4kKEKhPU57UAWr60OnwJf3MMUqyIUXJzgmsRDc3SSWccG1WTPTGa6DxlYQaVYJE/mkyuChD7gB7VnaeLtrKaWVGYONseflOPWgDLRLi9uo4NNjVPKAWTB+V8VPLt/smaKRYpHEuCB1B9qlS2aytFa0iJu2yu3dwD61Xk0y4tCsl40MMj/ADMu/J9yKAKgZbWRJLeJ4jyCfvce3vVedwZPKRgxHTPU1els7OImQ3kjKORGBx+dRldsrNLbGF3Hyuw4x/jQB6f8MvELw2awtJmSJtpA9K9l0+7W7gVwRkjnFfLnhrUhb6oQg2owAO2vZfBmu+VObd2yjHIPpSYHpFFIjBlDKcg0tIZ+dnx0IPxD1DHA3y8f9tpK7/4W/wDIiaZ/21/9GvXn/wAciD8QtQIAGXk/9HSV6B8Lf+RE0z/tr/6NegDxXxZ/yNWs/wDX7N/6Ga+rP2Ix/wAUf4iP/T+v/osV8p+LP+Rq1n/r9m/9DNfVf7EZ/wCKS8Rrn/l+Q4/7ZigD6Trz34yORpNkobaWkbr9K9CrzP455/sfTjyF85gxHpihAeLzFoZSBtZ+vPcUktwks5kRBG+BnaehqRZJDIIoEBwcKzelTxbRIIzBHJIDnI4z9aoRXhy8v7/55SPlcVLaR31xb3F1Co3K21wx6Crk8MVjGYp95Enzr5RB2e1VWUuZRaXPyEAtEepoAs200UZWP7KrSlh5h3cEeort7C50y+sbmO8EWnBU2xu4DFiPSuBjNxBMqtbkGVc4xkKPXNWHQ3YgjuVZY1Jw5HBoA6nRdSeztJ442hlbOIt4wJBXMnT72O4CLApWSXdg4JU56fSuhs/3FsohtDdwJEQMH7h9ahk1C3trJrmWNwygARdH3UAaU2k3VgsaX4SNpedgYcD3rD1VbmwiSOPbLFGd2R1A+tVbpzfS3bMtw88kQ2b3JxTdCuIZZlk1MSQ2rfumAztJoAkeWS5iN2LGP7PuG5n+XaatJaWt64xPFb3EnAzwTSeLIrZLhY9MleddmNnUD0qPRtFvbuRDNHkj7zBeY+O9AHQeH9C0yaRodW1sLKhxhMDJ7Z+la0vhfw2/7u61eeZiwJlkIC5968k1DT5NPu5I7u3kWQMSs244cE9qeloLhVjlctlh8pYn+tAHYePvBk2jXsUtjfW1zaz8JCzBZFwP1HvXMx2kiqWkj2BTktnk/Sna5p4tbi323DTPGvy87gvtUli4vY5RcKyP1WRTkIfegC3o0xS9SSZJY7V2ALgcV7Zohi0HQ73ULlx9ljj81T0OAOn48V48gWWCOI3ibU/2cZb0rtfF13I3w8+xB8mSMb2Hf0FDA8b8Qa/eeINWudTvXcmZjsjDYEa9AB+FUEuGQjqcHqTzUJRoxtKHcODmlUHdngHv3pAe4fBvWZbtxblsgDDCvX68C+AUMr+Kr5gT5UVuC3HG4nA/rXvtDGFFFFIBkwzGwrw/4hQJD4mgchDHOvz722nAPavcZceWc9K8R+MFuZ7+0lRA5XIyewpoTOaungutRcW8yW4UDOWJytRasbTSbq2ewu47zjLcZBB6jNZVpbW0kipdrPGqZJcDP6VBcRw2VwCLlXUnKIq4wPemBoyWV3Zanbvp5aRrk/u/LGQAeSDVnxPptxbQGS4VsB1bZjo3eu4+DFlGlnPq80LujPti3j7vuBWj8T9btJ7VLS2EO6RvncgZ4oA891DWr6609dM2mNMqpbgHHoKxptIE0rOl+sgDAbUHzg/WrF8VudWiZtPuFRsIJM8H3q3PpEmj2DXKGMoDlYs/Mx9SaAJJza6PBBbyNNNdMhYG45CfSsmK4TUWM813MpwVMajjI6Y9Ks3F7FqCwza0snm8IrJ2X6U0pYRzLK1yIYXfbhByPc0AZFsJWjlacT+VI3lhjwSfarT6ddzT5u4UWREG1mbqg9fetDUobia1gns42uI7YkMydD6GopG2xw3UsZldjgBmzx7igB1z9jNgEskbCncSRnd9KpahJdyTW7SER2e0YLrnd71aj1I3ElxLLF9nhRCpWJfu+mKy9RmuxaRpNJI1oufLAIJPpQBPdqg1NXWWPdgbjEMDFdPoeovE8fz7THzyeSK5GU+TY2itEqu3zbSO31q3pcs0l0GRgV/j2jpigD6U8JasNTsBu2h1HOO9b1eTfDDUv9OWMH5ZDjk16zSYz87PjoMfETUBjHzycD/rtJXf/C3/AJETTP8Atr/6NeuA+OZJ+IV+WI3b5M46D99JXf8Awt/5ETTP+2v/AKNekB4r4s/5GrWf+v2b/wBDNfVX7EZ/4pXxEMj/AI/VOMc/cFfKviz/AJGrWf8Ar9m/9DNfVP7EZ/4pbxGMf8vqf+gCgD6Vrgfi7ALvwmZQCWt5Q3HOK76vOvG98fJv7NcGN0IOfX2989aaA8SwJfKQnA3YLjjNaUqpYXjWwlj8pkCn1GaylZkLGUbghwwNaOnQ20trOrhBMTuCkc49qYi9Z6JayyTi6vNkaLuWYHOPasiEWsENwdyzkZVXU8/WrsUBbyxHItuG4ILZB9jTLIQj7XBaCJblPmDyd29qAL2ha4bPw+9s5DvKCdrjlvYGqcl08UVm0hdWYnCZyoz0pmkpDNOzap5hkwdiocEv7VY1O0aARLqFs8O4jOeu31FAFm3h1PSg7x3KlHGcdB+VZ14Zri6E985ZmAIK8Z+lWJ7qa5t5BE5EUQLAvwePfvU1rdDz7aa9WOaJgCWB+77YoAu2M501poo4JXe45Xz+pXHarML22r6Xd2IuLa12uHRn7kHpWjqlzaXsIms/+PiFAYld+CvcVzliLC8edLq2SOTgtIBnOfSgBHg1FBNLEyxiMYJAGGHrmuz8F+KbfR/DN0LyMSOcsQTy5x0+lcfZSSrZ3tpuSa1X5VKctj/GptI8P3JtpY7yZIbV1HzSDkL/AI0ATweKbTWpGg1XTxBbSMVXPzBR9adq/hadYTNpcgdmwIsNlSvtTNNsdLBeCxuPPlQkBmOcfSqupG60u4j+zybVQ8Rk8Ofp2oAoy2Munziwu9ssbEOyp/rF/wDrVUmuA9zJDDHJHAOdqnlvrWxJcy3JW7W1C3StgrIPvL6fSqF3M6ytut1gyckdCP8A61AFm2VW+VI1wf0rvrWxOq+HpInLAcBSO2K88gZ8Yt5VkUkEmuj0XxHe6VJ5EJjlDDJR+g/GgBbn4fXUpBVcZ4Ge/vVaL4b3iSMJCpAOcqO3v+tek6N4qhuFgVUG7HzljyDXXQ3EEycEYxk54pXA5j4ceGovDumTttxNcuGcnuAOP611U7EBcc5PrXnXi7xkqXb2Fky5DeWpHQ13sSH7Ba+cSCqLu7c4oGWlOcYNPqCEqT+7Hyip6QDJv9S+Tjg814l8SbtRqEEKrI4IY7lPSvY9Wn8nT5HwcHivAPHrvNrUHDFAew5poRhxKIrKW5FyC+cKg5LCq1vbj7QtzqMYkhkPyqOmasrcXGlXDmWJDMwxHtXK7T61DBOjoJbk7oo3JVT0L0wOmvPEmu/YIrDRkjttOUfv5OAQPauVZLjVbq3trESXVzI+0MOcGpbmeSO3C3VmBM5JBycMKs6bqM8Eq/2RBHbP98uud26gD0w/Cu5vNJiS81me3ukAIEXzIpHrmuI1HS7iFpPtV7FLJaMUwOVYetWda8TeNL7To7WXUY7O2kG1pFUK7j03VzUdpdW7pItzHKrfKys2cj3oAtz2N6LJ50jhzAC27sw9Kr22nyyWdzd53+YmdgOCtatjYveD/Q53WJYyGjf7u72qDTdFuJ3d7rUVt+zbjjigCz4Z1OBof7LMkkDtH/FjD1l6w6DUS0JBe1AGI/uvmrs2h6S1xvutVQLn5dgxv/Go90ltJcwI8D2iR/IIR8/4mgCBbBbrQpS10IdReXiJuFArKiFlpWqFb7fqMsfIjj4TPqazj5krG4naZFZTyWyDV+SPzbCzaAxRsw3SFhlgtADNTnfULkTPOqn+GHP3B2FCh7B2jlDJI3VwTyDTpFyHFoglhY585UxhqpT+c/l+bcOT90nOST/SgD0X4WzKdfs4xjDSAZ9a+g6+fPg1G9x4rtSwO2IOxPHZT/8AWr6DpMZ+d/x6UL8SNRAx9+T/ANHSV3nwt/5ETTP+2v8A6NeuI/aCXZ8TNRGc/PJz/wBtpK7f4W/8iJpn/bX/ANGvSA8V8Wf8jVrP/X7N/wChmvqn9iI/8Uv4jGf+XxOP+ACvlbxZ/wAjVrP/AF+zf+hmvqf9iJR/wjXiNu/2tB/44KAPpevN/itbCHyLtc/MNrAV6RXPeO9MGpeHrgbS0kIMigdTjqPyoQHzhO7vM4BXYzBju5rcvmtL54XtE8uNVwz4x1rKmtD50oVGMWTyD0qSO3EYjje8V7Zx8wQ4x7GqEWP7HmtoCsRa5ik/1aryAf8AGqMMebhIpomhlXK5K8n2NTQXMtrH5WntI6o+9VPQH1zV2OSNbprme4a4uWGQCMKh96AIH0bUrCRJuGETgjPTnpWxq0jX6WD3fy3bvtZC2Qv0rLu5lkSO6N1JJubyygbp+FXrfU1hubdmtmZR0LjOfpQBPq+na3BNEL0xvaxZ2wbANydjmsKeO12q2n+Z5+d5h6hDWjqV/qN7eFJAxkZsJ82CB6VXt0tY7kteTmKVTh0X0Poe9AEUwJiguGutku35k2/d9qdusG23CGZnA+ZAcA067vvLvZJLB/3aLjBXdvqvbySPexwpahvP+XLfLtz3oA1bvVvs+jm40vTViLnazgfrUFpdXmrQo97ITbowRlz2PfFa8sAtNHe2XfIkAzIFGc596zItAmMZkgDzJOm5cH7vsaALt4tva6tZfZViiw2CScEio/G8gXWrXzoTkqGEsY9PWqi6XPDqmnorxtcyYJV24XHY1p+Kbq11idY1SS3NmCkzRgkZoAztQuBe6K81ysqSJJkSZwX9qrws2rWjzLAXeH5TgZyKSxuJLSVRM4urGQbCTyq++K3BdIulSx6LJHbtGSXbH3z60Ac3G3knzBhVAIORjn2961Us5bXR4r1WQ/aSUC5yceppllBNfLaRz3KMyvl1A/h9M1c1KCHTZytqRLA/yiInJjJ4oANFlkhZS3yr6t3r2Dw7bSXmmLLOrxb1wpPBIqDw94Stbe2tJdRQXFzGoZVYfKh+nrXV0mwPPrn4dpNrNvdC5AgSUSOh6nHYV300YkXBPy96fRSGRQxLGTsyB9afI6xIXcgKOpNMup4rWB553CRIMsx7Vwet+LYLm3mEbBdpO0HuKANPX9fha3miQDpwWrxXXVNxci6mdZFYnaI35rS1DXPOZvMBxg9Dg1zQvZIy4SNSJBjLjgCqEIkhcyuZGgQLtJYcfQH1qHC3lv8AM4VBykYHJIr0HQdJ0yfRCs8ccsm3JWQ/dJ7iuLubc2tzHNBbytHFIeQKAMmKGeS6aRnkZgAMAcL9av2dwthFcPcb1Zf9SQevufao5Yrqe8klty0QkO59xwBRp2nzXnnTS/vYohkknj8KAOys7yy8WeEntpohHe2+TuT+8O9cMIZXlmfzdksJw0YOOPWlsL66sr1rqzwi8qY89atX0K3rSXSD53UEhuMsKALfhy6L25Vroq0LeYoX+Op/Ek0Wo3Ynuo/s0IQZVW+Zz9KyLdZFjSNJIoWk4Z8449qs2cSy30kd/MZoFHLAZzjpg0AWHtYbDRPLuoALiRt8bt/CO2axpntHt4IrZ3OoSvjdjCN7ZrX019Lubkw6010YwxWJt3OO34VWube3txOLEtcmNzhj0T0oAhvbdbPTfst5OoDvkKo5A9atRQnULd3ivYI4LdduzozL/Ws66uri5tUQQnzVb97JjJ2+ntTbqSA3TGdiCECxrGuBn3NAE6TRrAtvGJIlyCGZvzJ9qr3MQhbzEeJlY7Qw9aWfeDH9rPmTAZ/d+noahijgZzJL5qIGyQT2oA9c+AdgzT6lqD8hVWJcjuTk4/L9a9kri/hJpqaf4QhZV2m5dpueuD0rtKljPz2/aG/5KdqP+9J/6Okrtfhb/wAiJpn/AG1/9GvXF/tDtu+KGpkcjc//AKNkrtPhb/yImmf9tf8A0a9AHiviz/katZ/6/Zv/AEM19TfsRD/inPEhyf8Aj7Tj/gFfLPiz/katZ/6/Zv8A0M19TfsRH/infEg/6ek/9AoA+mKCMjB6UUUAeCfE/Qxo2sfu0K2lwd8bLxj1Wuc863ji8i3QRuF4OMkmvoPxfoMPiLRZbOXAl+9FJj7jjpXznc2stlqb2V/G8bwsUcY5P0qkIktpzbrO067zINiYONretQS2zx28tsQ8j4D5/wDr1p3miTLpAe1j8+3Y5Cn761Fa2skMLSebhcBXz1NAGjoulwzWRldSowMqxB2n1rPe3uYZ0WKQS2qSbg7MOPWnQwo+bc3LDJztU8sPSnS2cVyBBBdrFCpPEnGfagButqJ5leCby4D/ABF+d31qnbaXd3kMkreU0UYzvLc1atbSJLtrbUxM8LJ8hQfJn61DeTRxSobZgbKFTGYh/WgCQ29nvCv+6crhVDYDH1FORt0DyruinXCcnn8PWq11YkraShQ0cjfdHJArRSJ4obqQp/o6DAWQYZfQigCxKboaRdxNDNGwQfOTy9UNJvb2wliRriSLcvTqAO3FWbe9Vo3McrSMU24Yk4PtUmmW8gukluyrRgYwwznPpQA6G7U6pG2pzl53JUOBgBT3qKSS7t7m7ghkTyvu4A+8p7+9Ps7aK9nuY7iBtkIZy69VxyKbNc2+qPFJLNsCRFY/LXDFh2NABZ6c9taSTWKktDJkhz8svsBV8X1t5zQ6vZ/Yo7mPfviwCv1FY8N007qLt5UhgwYo1GAx71Y1/U7fULZJooGRY/lO9CelADr6SeGaC4tYA9rCP3bqQA3ua0vD1ob/AMa2QkURw5WZ42Odzdv1rnLy6810ktjsgKjdCOmfpXovwm0iSW8e9nGUj5B65PYUAetUUUVIwooooA4T4t38ltpFtBHkLLJuc44wO1eQzX24IYvvkfOp7+9ev/Fi0nu9JhEalo0YscevavExbyiVLd1aOY87m7D1qkItPClxb4OJDn72cY9qms9IM88MS3UEcbDaQ3LJ70zT7SEXxguZyRnIZThSaNQSJN8On7prhvl3K2DnNAF68s7bRdVht5dWa5AXcjAYH0NVJtZnk1KEtPH9lYnKRrgZ96oNYx2FqbnUZUluX+XaH3bf/r0/e8ttGZI41tvuxtwpBoAbqVq1zNK1l5zRM2Co5Bre0G5tdE0Se1nMb3NySNrD7vtWdo1zNFdyJKRCjx5EoPCAf1rDurtLmOWIF7i4eXdFLjJoAmt9Ik1O3eKyBbUxJjaTgYq/BpwsIpYNRby7mMbjk8A+lW/DT3DXEttZRsZVTMm/gr7g1U1S1Mt4/nXn2mMthj1K+xoAzhNb34SO+RWeI7YWQ4DZ7fWrsUVwbciw2Oyod0R5K/Wul03wAi6Z9tt73zL3BEcRIIHvXF2v2m01G5hEv2cJ8k7jncTQBDq1yY7W2Zgu48NjgiodQhVbC0ntdxin++wY8fWtjRRDaJM80KXmSVjeQ5Cg98VP4d1SztrK4s5oRNHI7DBXJGT1HtQBiFofsyx2tz5Az+9XqW/GpUuJpEuFPlyWyLgyMuMemKtz6To9i84N20jjLqmc59jWPHeSzXUKsBtLcxhsAj3oAr2MrW08ksWwbsqA3NaOh25v9Qitk+5Iw357DPNUkEUUsjeSOGOBmux+HumyXupwxxJ+8kPOP4RQB754WBGlx8bYgAsYxjAFbFRWsK21vHDH9xFCipakZ+ePx+/5KXqWM/ffr/11kruvhb/yImmf9tf/AEa9cJ8fRj4l6kM5+d//AEY9d38Lf+RE0z/tr/6NegDxXxZ/yNWs/wDX7N/6Ga+pv2Iv+Rd8Sen2tP8A0CvlnxZ/yNWs/wDX7N/6Ga+o/wBiI/8AEi8SD/p5j/8AQaAPpuiiigArgfif4PTW7UX1qpW8hU7tvVx/jXfUyVdynHWgD5qgvb43EVu032d7ddhVuA31qp580d/OHTzgeoB4r1L4j+E47wi/tYcXOD5igcOfavMbtGMoQoYGUbGIHGfeqETx3KpcDYB5g+ctgfLjsKh0xrO9v8askn2eViQ8Y5B9abp9rFcTBVyGQ9QMg1avZ57Fx5MSxAcOqryV9aAL2mxSWkd+WWW606EnyTn5j+FQQajbfYLrFhHtdMA5+b6/WqhvLqJ4buzl83DfND149xS3WlNJIbxpzBaSHLCQYH0FAEduk9sVurl3ctHiMKRwParFnNd3ErJfOZ450K7e4x0zUFxLbXNyqKzxxiLbDtXv6n60ze9uvmxqElfhTk44oAmuJ1ghFutsIos5H94Gr+26t7Yai0BjgkIWIN0c+1VtWvbDU4LNvs7LcqNkrA4APrViDUZ9U0xNNmRxbWrb4wGyV96AHxJdvb3kV0yRGQcN90t7VlQ2IzsUqtxDiVXU8Een1qa484sw2yzwI24Sk5CH0NZ0byuXnjYbnOMAYFAD573zZluZI9kxGBgcVYGrXj6esJG61Lc5UcGp7W+t1tZo5LYSE98fdpl7dWslpHBY28hlYhdgXOT2+tAF/wAGaS2vavBaCMhUJZ3Xpgete/6Xp9vplmltaIEjX9T6mue+HPhkeHdDTzxm/uAHnJ6qT/D+FdZSYwooopAFFFFAFfULRL20kgk6MOvoa8H8daa2narhzJkDGVFfQFcD8WtNlm0pL23UHyjiTjnHY00B5NpcdkJJJNRaVSO+MlR61WuJo/tMb2UkQjGRnHzEf40G+85gtzu2kAEIuCR71S8hIrou3EeeFb+tMRLY2S3tpeCWREVZNwwMmn2FqpIkz5ksPzrGzcE/SnXrQ2tpBb6a6k3D/vXbsfTNKi/ZjdxQgeYUVTIvOD7UAJf6mtq7xzW+A+DIuM7V9quC0sdIt7PWbGJ5bO5Jj3Z3bD9KqXWm2hWD7VdBnZSXZTzx61Tsp4SqwCWRNPgJ+ZfuigBIIZh9qiieWO9lk3ZZyMj0+launx/2dbFNsDrcnZJIT91z6GsmePerukjyymQESs/Rfar01oDbhSHlijXzAVIBJ/z3oAZqz6loeovHDfzImwFHHIOewrFhWZIZ5HlLvIdxB5P1NdQWj1Hw9b291uGoM58pjj5R7mucmWbSZmieAOxxuYj7/wBDQBXLmORU3M6cBSPU9qu24jtkuSGld+BzjP4VpX0OnKYpElMcLQ+YCFxhu4zWRZagTauDCrDOQ5HOKAKqXXlCQbA1w55bGcLT2twsKXSxpGTwFJO76imu0MpYrb+WxGcA9qlSUYTG6RsbUQDIAoAicM+3dhnY4Cry2a+ifhX4YOjaQl3dx7by4XO0jlF9PrXMfCjwCUMWr61bgEDMELj/AMeIr2Gk2AUUUUhn54fH0AfErUgowA78Y/6avXd/C3/kRNM/7a/+jXrhfj8SfiXqeeod/wD0a9d18Lf+RE0z/tr/AOjXoA8V8Wf8jVrP/X7N/wChmvqP9iIf8SLxGc/8vKZH/ARXy54s/wCRq1n/AK/Zv/QzX1F+xFn+xfEfBx9oTnt90UAfTlFFFABRRRQBVv7UXMYH8Q5FeTeN9AnU3LRKd7fM/uK9jqlqenx3sRB+V8YBpoD5vt5nhgFvt8pkbIkHWl1S4uLoJLcMRGCEPl9TXb+KvCM1nK0sYDoeSQK4eaGWOYeecxpyFI70xEcktvBKyWxaNGGDKBgj2qS5nnvFjtLiTdEo3LvPA+lRSyqbZSIj5jNkU+4gYASpP8p+VgP4T6ZoAntbpIB5d8m2LHlqV5NVbpbmZgluQ1qv/LRhwKY32ebyHZpAV7YzgirGq3yykxwRmK3kUZHYn1oAZbT2gv1E7AwAYfC459qc93GmpvNbArDtwAG6+1U0VVITaxY9HzkUJIPlE7bkAIbHUUAXk1S4tBOlsi+VKuGUk8H1xUFpJI1vKEkRGzu2jkMaikiQRCS3ZpQeGUjBq/pGkS3rLkbIlHzBTkmgAsbG51KYR2kEjztwSFwv1New+BfA0GiFb6/KXGosARhRsi+nv70vgnQ1trcNGjJG2CzEYLV24GBgUmwCiiikMKKKKACiiigAqO5gjubeSGZQ0bjaQakooA8J8Z+EZdHvpbjSQXi3FmVhkj6e1cHcqFVhvUu/zNnt7V9M+ItNe7hMtsB56jGD0YV4n4g0eKeZjEiQ3O75oh0zVIRx0cMkjpFGrNG3zbR1GO9Xre+WONvsSg7T8xcZLNVe4a6s53AYqx+VgMdPakginkcg4jAXO49R/wDXoAfcXEi26McrJLneAM1XeRrbTjatGxWV97+2Kf5aSlTcSAF87F9PrVYXRti4Zo5ocEEnnmgC/Ywv/YstxGu35vLVs559hVb9wsgNvLI+0bXYt1b0ptxcTQ6PZQooVSTIxPA9sVTNxvtFt/Ij3l925TyxoA045prm0McR8xsn5VwWH40tpNI2lOLyDzo4mwjOcEe1VEhktmRLchZW+82O/pxUkkoAELJ5kMfLhs4ZvpQAq3C3E+U3LCqncj9B9KhSZoQylEIfoxPAHrUnltK4nlaKNWPyA+n0qeysLzU50treAzmQ5woxQBAtjDcOVtXMjuQAGOM16t8NPhsUaHU9dQgqcxQE/e9CfatzwF8OrbSzHf6qiS3Y5SIcpH/ia9GpXABx0ooopDCiiigD87/j3z8S9T/33/8ARj13nwt/5ETTP+2v/o164T4+hV+JmqCMAKHfAHT/AFj13fwt/wCRE0z/ALa/+jXoA8V8Wf8AI1az/wBfs3/oZr6k/YiYjQPEq8bTcxn3zsr5b8Wf8jVrP/X7N/6Ga+of2Ij/AMSbxKMH/j4j5/4DQB9O/TmjrRRQAUCg9KKACiiigBk0STIySKGUjBFcP4k8FQzxO9oo67tpFd3RQB4Bqmh3VmS7xE9gCOBWN9lnLGJsbXbJHWvo+5sba5QrLErZ9q5jU/A9jcbmgUI56Y4p3EeJQ2c0kkkfyRhMscttOB6VLIsCPDCvz+Yuc56fWu/vvh5NjEMZK89+ayW8FapE5EdrJ0xyM0wONnhfyTKkqiIHAjB5U0tojvlUTdEeW3V2en+BtU84lbJ8t1MpCgV1GkfDlY5N+oTrj+5Fmi4Hn+iaO09wq29uzl+AB6V6v4d8KJahJbwLu6+WB/Oui07TbTToglpCsYAxnHJ/GrlK4xFUKoCgADoBS0UUgCk3LvC5G4jIGecf5NLRQAUUUUAFFFFABRRRQAVzniHwrZapvnVDHdH+JTjNdHRQB4X4q8LXFgGaaPfF/A6/eBrip7GWFgu4ls7sEdTX1DeWcN3HsmXIrzbxP4IuA7S2imZMkgr1H4U7iPE44pBcRrKSSGOBjpVk20EjusLjcfvR4wMetdLf6JdW04LxspHGSuBj2zWHcWcqykqAjMfSmBnXVwjxLCf3piO0Hn5adtjis0uN2Jm4Xd1A9qnMDrLuKc9wFxVsWMsxJdg7HABXOAPYUAVN0YhEltO0e0ZKEZLGkW2+2TBkG0E8g5HHfNdRovhG9vZMW9sx5+864Ar0fQfh0kGx9RlR2xyqigDznR/BDTzxmaQSQsQQF6kV7N4V8OW2k26+XAsbY69TWxaaXaWixiCLbs6HvV2lcYdKCcAnniiikAUgJ3EbSAO/rS0UAFFFJzQB+ef7QARfidqixDCh3A5z/wAtHrufhb/yImmf9tf/AEa9cN+0AQ3xO1QjON79ev8ArHrufhb/AMiJpn/bX/0a9AHiviz/AJGrWf8Ar9m/9DNfUH7ERH9j+JB38+P/ANBr5f8AFn/I1az/ANfs3/oZrX8EfEXxT4GiuY/C2qfYUuCGlH2eKXcR/vq2PwoA/ScUV8Af8NB/E7/oZv8AyQtf/jdB/aC+Jx6+Jv8AyQtf/jdAH3+TjrRXwAP2gvidjH/CTf8Akha//G6P+Gg/if8A9DN/5IWv/wAboA+/6K+AP+Gg/if/ANDN/wCSFr/8bo/4aD+J/wD0M3/kha//ABugD7/or4A/4aD+J/8A0M3/AJIWv/xuj/hoP4n/APQzf+SFr/8AG6APv+ivgD/hoP4n/wDQzf8Akha//G6P+Gg/if8A9DN/5IWv/wAboA+/6K+AP+Gg/if/ANDN/wCSFr/8bo/4aD+J/wD0M3/kha//ABugD7/or4A/4aD+J/8A0M3/AJIWv/xuj/hoP4n/APQzf+SFr/8AG6APv+ivgD/hoP4n/wDQzf8Akha//G6P+Gg/if8A9DN/5IWv/wAboA+/6K+AP+Gg/if/ANDN/wCSFr/8bo/4aD+J/wD0M3/kha//ABugD7/or4A/4aD+J/8A0M3/AJIWv/xuj/hoP4n/APQzf+SFr/8AG6APv4H5iMHHr60jKS6sGIxnI7GvgL/hoP4n/wDQzf8Akha//G6P+Gg/if8A9DN/5IWv/wAboA+/6K+AP+Gg/if/ANDN/wCSFr/8bo/4aD+J/wD0M3/kha//ABugD7/or4A/4aD+J/8A0M3/AJIWv/xuj/hoP4n/APQzf+SFr/8AG6APv+ivgD/hoP4n/wDQzf8Akha//G6P+Gg/if8A9DN/5IWv/wAboA+/6K+AP+Ggvidn/kZv/JC1/wDjdH/DQfxP/wChm/8AJC1/+N0AffNzaW90u24hSQdPmGayLjwnpEz7vsoRv9k18O/8NB/E/wD6Gb/yQtf/AI3R/wANB/E//oZv/JC1/wDjdAH2pJ4E0d3LeWQT6VfsfC2k2RUx2qlgcgtzzXw5/wANB/E//oZv/JC1/wDjdH/DQfxP/wChm/8AJC1/+N0AffqRon3FA+gp1fAH/DQfxP8A+hm/8kLX/wCN0f8ADQfxP/6Gb/yQtf8A43QB9/0V8Af8NB/E/wD6Gb/yQtf/AI3R/wANB/E//oZv/JC1/wDjdAH3/RXwB/w0H8T/APoZv/JC1/8AjdH/AA0H8T/+hm/8kLX/AON0Aff9FfAH/DQfxP8A+hm/8kLX/wCN0f8ADQfxP/6Gb/yQtf8A43QB9/0V8Af8NB/E/wD6Gb/yQtf/AI3R/wANB/E//oZv/JC1/wDjdAGd8e1CfEvVFHQO+P8Av49d58Lf+RE0z/tr/wCjXrxHxBreoeIdUl1HV7j7ReSkl5Nipkkk9FAHUntXt3wt/wCRE0z/ALa/+jXoA7bVv+Qre/8AXZ//AEI1UoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvQPC3/IBtf+Bf+hGiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple small perivascular nodules, due to metastatic small cell carcinoma, are scattered diffusely throughout all compartments of the lung.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Talc granulomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 349px; height: 231px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Talc granulomatosis in an intravenous drug addict with multiple, partially confluent, bilateral micronodules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_61_4054=[""].join("\n");
var outline_f3_61_4054=null;
var title_f3_61_4055="Balfour retractor";
var content_f3_61_4055=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Balfour abdominal retractor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 511px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is a self-retaining retractor shown in its common placement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_61_4055=[""].join("\n");
var outline_f3_61_4055=null;
var title_f3_61_4056="Treatment of knee injuries in the young athlete";
var content_f3_61_4056=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of knee injuries in the young athlete",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/61/4056/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/61/4056/contributors\">",
"     Albert C Hergenroeder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/61/4056/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/61/4056/contributors\">",
"     Joseph Chorley, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/61/4056/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/61/4056/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/61/4056/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/61/4056/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/61/4056/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of the treatment of knee injuries in young athletes is the restoration of maximum function while preventing recurrent injury. A successful plan requires making the correct diagnosis and initiating appropriate treatment, with a staged approach to rehabilitation.",
"   </p>",
"   <p>",
"    An overview of the treatment and rehabilitation of acute and chronic knee injuries in the young athlete is presented here. The causes and evaluation of these injuries are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28455?source=see_link\">",
"     \"Traumatic causes of acute knee pain and injury in the young athlete\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=see_link\">",
"     \"Approach to the young athlete with acute knee pain or injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29223?source=see_link\">",
"     \"Approach to the young athlete with chronic knee pain or injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of acute knee injuries can be divided into four overlapping phases. The first phase involves prevention of further injury and control of pain and swelling. The second and third phases involve improving strength, flexibility, and endurance, while continuing to protect the injured structures. The fourth phase is functional rehabilitation.",
"   </p>",
"   <p>",
"    Chronic injuries are managed in the same four phases and in accordance with the following principles:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The correct diagnosis must be made. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29223?source=see_link\">",
"       \"Approach to the young athlete with chronic knee pain or injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anatomic, training, and environmental factors that contribute to the injury must be identified and modified as appropriate [",
"      <a class=\"abstract\" href=\"UTD.htm?3/61/4056/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Appropriate therapy must involve a rehabilitation program. Patients with chronic pain already know their limitations; they seek medical care to find out what they are able to do without further injuring the knee.",
"     </li>",
"     <li>",
"      Flexibility, strength, and endurance should be rehabilitated simultaneously.",
"     </li>",
"     <li>",
"      The duration of the rehabilitation is directly related to the duration of symptoms. The patient with years of patellofemoral dysfunction is unlikely to be asymptomatic after one month of treatment.",
"     </li>",
"     <li>",
"      The duration of rehabilitation increases with the number of associated injuries. As an example, a patient with isolated patellofemoral dysfunction is likely to recover faster than one with patellofemoral dysfunction on one leg and an ankle injury on the other.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHASES OF TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Phase one",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of the first phase are to control pain, prevent further injury, and promote tissue healing. Athletes who have acute knee injuries with obvious deformity, crepitus,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neurovascular compromise should have the knee immobilized as comfortably as possible and be transferred to an emergency department. These findings suggest fracture or ligamentous instability and require orthopedic consultation. The decision to refer athletes with acute hemarthrosis, but no obvious deformity, crepitus,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neurovascular compromise for orthopedic consultation depends upon the training and expertise of the treating clinician. Primary care sports medicine clinicians routinely treat patients with acute knee hemarthrosis and refer them to orthopedic surgeons as appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=see_link\">",
"     \"Approach to the young athlete with acute knee pain or injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Knee injuries without deformity or neurovascular compromise can be treated initially with rest, ice, compression, and elevation (RICE).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     RICE",
"    </span>",
"    &nbsp;&mdash;&nbsp;RICE treatment involves rest, ice, compression, and elevation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rest &ndash; Patients who have pain with weight bearing or have clinical signs of instability should have the knee immobilized and be given crutches with instructions for their use (",
"      <a class=\"graphic graphic_table graphicRef63565 \" href=\"UTD.htm?8/56/9099\">",
"       table 1",
"      </a>",
"      ). Immobilization with a six-inch elastic wrap usually is adequate. Straight-leg immobilizers offer no structural support, and are not indicated in acute knee injuries (although they are commonly used). The specific type of immobilizing device depends upon the type of injury. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Acute injuries'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Ice &ndash; Ice should be applied",
"      <strong>",
"       at least twice",
"      </strong>",
"      per day, and preferably every one to two hours while awake, during the first one to two days. The ice should be placed in a plastic bag and applied directly to the skin for 20 minutes. Control of swelling is more likely to occur if ice is applied more often. Effective cooling requires that the ice be kept in place rather than removed intermittently when discomfort occurs. Bags of frozen vegetables are inexpensive and make sufficient ice bags; more expensive icing devices exist, but are not necessary. As a general rule, heat is not used in the first phase of treatment.",
"     </li>",
"     <li>",
"      Compression &ndash; An elastic wrap or tubular stockinette can be applied for compression during waking hours. The six-inch elastic wrap should be applied starting from the mid-calf to approximately 10 cm above the superior pole of the patella. The wrap should be removed for icing and reapplied afterward.",
"     </li>",
"     <li>",
"      Elevation &ndash; The leg should be elevated as often as possible throughout the day. Ideally, the degree of elevation should be to a level above the heart. However, in practical terms, any elevation is better than none. The patient is advised to prop the leg on an adjacent chair at work or school during the day, and to elevate it higher at home. Elevating the foot of the bed promotes venous return and may reduce swelling during sleep.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nonsteroidal anti-inflammatory medication should be used in the acute period (first five to seven days) to decrease pain and prevent a pain-disuse-atrophy cycle, or, in the worst case, the complex regional pain syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37768?source=see_link\">",
"     \"Complex regional pain syndrome in children\"",
"    </a>",
"    .) More potent analgesia should be used as needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Arthroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthroscopy is a useful diagnostic and therapeutic tool in skeletally immature athletes who have acute knee hemarthroses, which usually indicate significant pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4056/abstract/2-8\">",
"     2-8",
"    </a>",
"    ]. Approximately 50 percent of young athletes with hemarthroses have anterior cruciate ligament (ACL) injuries and an equal percentage have meniscal injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4056/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, between 7 and 67 percent of osteochondral fractures in young athletes may not be appreciated on plain radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4056/abstract/2,9\">",
"     2,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Arthroscopy is the most accurate method of diagnosing the cause of internal derangement. False-positive results are rare, and, with the exception of posterior horn meniscal injuries, false-negative results also are rare. Arthroscopy is used selectively as an adjunct to the history, physical examination, and MRI when there is a diagnostic dilemma. The only absolute indication for arthroscopy is mechanical disruption of normal knee function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Initial rehabilitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is essential to maintain quadriceps strength in all types of acute knee injury. Quadriceps strength can be maintained by performing pain-free isometric quadriceps contractions, called \"quad sets.\" These can be performed in one of the following ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As straight-leg raises with the patient supine.",
"     </li>",
"     <li>",
"      By actively extending the knee while in the seated position. The patient is seated with the buttock at the edge of the chair and the heel resting on the floor. The knee is then slowly extended (sliding the heel along the floor), stopping at the point of pain.",
"     </li>",
"     <li>",
"      With passive knee extension, using gravity. For the patient who cannot actively extend the knee because of pain, passive extension can be achieved by lying supine and elevating the heel on a support, such as the arm of a couch.",
"     </li>",
"     <li>",
"      With contraction of the quadriceps muscle with the heel in contact with the ground or on a support and the knee in full extension, once the patient can achieve full extension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Quadriceps contractions should be initiated as soon as possible after the injury; they may be started on the day of the injury, provided they can be performed without pain. Sixty to 100 repetitions in sets of 10 should be performed per day until the athlete is using the leg normally. In the acute phase, it may be difficult to perform quad sets in full extension. Modified quad sets can be performed by propping a rolled-up towel behind the popliteal fossa to hold the knee in slight flexion. A physical therapist will be necessary to facilitate quadriceps contractions in patients who have acute hemarthrosis. The physical therapist also can teach the athlete how to perform the contractions at home.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Phase two",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phase two begins when inflammation and swelling are controlled. The goals of the second phase of treatment are improved strength, flexibility, and endurance, while continuing to protect the injured structures. The second phase overlaps with the first in that isometric quadriceps contractions (quad sets) have already begun.",
"   </p>",
"   <p>",
"    \"Relative rest\" is the key to rehabilitative therapy of acute knee injuries, as it is to the treatment of any musculoskeletal injury. Relative rest means that the patient can perform any movement or activity, as long as there is no pain or swelling during or within 24 hours of the activity. Athletes who return to practice or play despite pain or swelling increase the risk of developing further injury.",
"   </p>",
"   <p>",
"    The relative rest strategy is based upon the inflammatory response following injury. The initial inflammatory response to injury includes migration of fibroblasts that produce collagen and result in formation of granulation tissue. Granulation tissue is tenuous, vascularized connective tissue that is easily disrupted. A balance must be struck after an injury between immobility to promote tissue healing and early mobilization to prevent atrophy, scarring, and loss of flexibility, and to foster endurance and proprioception.",
"   </p>",
"   <p>",
"    As in phase one, a physical therapist is essential in helping the patient understand rehabilitation and relative rest. Active and passive flexion and extension (range of motion [ROM]) of the knee should be started as soon as possible.",
"   </p>",
"   <p>",
"    Improving ROM can be facilitated by the application of moist heat before exercise, as long as the exercise session ends with ice, which will limit swelling and inflammation. As ROM improves, hamstring- and quadriceps-strengthening exercises against gravity can ensue. As these progress without pain or swelling, resistive exercises can begin, with an emphasis on quadriceps and hamstring strengthening. Initially, the resistive exercises are low-resistance, high-repetition (eg, 3 sets of 20 repetitions).",
"   </p>",
"   <p>",
"    Quadriceps- and hamstring-strengthening exercises include terminal extension (ie, the final 30 degrees of knee extension) exercises and hamstring curls (done lying supine and flexing the knee within the pain-free range) using an elastic band or a 5- to 10-pound ankle weight. Quadriceps and hamstring endurance is improved by any aerobic activity of the quadriceps and hamstrings (eg, swimming, cycling). These are to be performed in the pain-free range of motion. Although the exercises can be performed at home, we recommend that patients receive training in how to perform them from a physical therapist. The physician can write a prescription for a \"home education program\" for exercise such as quadriceps and hamstring strengthening, flexibility, and endurance exercises.",
"   </p>",
"   <p>",
"    Depending upon the injury, certain exercises are to be avoided and others emphasized. The rehabilitation program described in the preceding paragraph is appropriate unless other exercises are prescribed. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Acute injuries'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Because an important part of rehabilitation is psychological, during phase two the athlete should attend practice with his or her team. During some of the practice time, the athlete can perform rehabilitation exercises and work on upper-body strength.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Phase three",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of the third phase are similar to those of the second: achievement of near-normal strength, flexibility, endurance, and neuromuscular control, while continuing to protect the healing structures of the knee. During this phase, resistive exercises can involve higher weight and fewer repetitions (eg, three sets of six to eight repetitions) to increase strength and power. Endurance of the hamstring and quadriceps muscles can be increased with cycling.",
"   </p>",
"   <p>",
"    Neuromuscular control can be enhanced with specific exercises, such as balance exercises, resisted band exercises, or jumping on a mini-trampoline, facilitated by a physical therapist or an athletic trainer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Phase four",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phase four involves functional rehabilitation. The accompanying walk-jog program (",
"    <a class=\"graphic graphic_table graphicRef68511 \" href=\"UTD.htm?15/18/15660\">",
"     table 2",
"    </a>",
"    ) allows graduated progression. If at any point in the progression there is pain or swelling, the athlete should take two days to rest and then return to the level of activity at which there were no symptoms. Once he or she progresses to jogging 20 minutes without pain or swelling for at least one week, the patient can sprint straight-aways, and jog turns on a quarter-mile track. If this is done without pain or swelling, the patient can move onto the court or field, depending upon the sport, and run figure-eight paths over a 20-yard distance for two to three days, advancing to 10-yard figure-eight paths at a full sprint. If the patient remains asymptomatic, he or she can return to play without restriction. The decision to use braces after an acute injury is made on an individual basis; however, there is no evidence that braces are necessary in a fully rehabilitated knee.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ACUTE INJURIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history and management of specific acute knee injuries are presented below. The evaluation of these injuries is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=see_link\">",
"     \"Approach to the young athlete with acute knee pain or injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgery is indicated for acute injuries involving more than one structure (eg, a meniscal and ligamentous injury). Isolated injuries to the MCL, LCL, ACL, and PCL may not require surgery, and the initial treatment of choice is conservative. Surgery is considered at follow-up if the patient does not progress to baseline function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     MCL injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of isolated medial collateral ligament (MCL) sprains, regardless of degree, is that they heal with rehabilitation and no surgery is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4056/abstract/10\">",
"     10",
"    </a>",
"    ]. During phase one of treatment, bracing is not necessary for grade 1 and 2 injuries (stable with valgus testing). Grade 3 injuries are treated for four to six weeks with a hinged rehabilitative brace, set with a limit of 0 to 90 degrees of flexion initially and then allowing increased flexion over time. Rehabilitation during phase two through four is as described above. The use of an MCL stabilizing brace may reduce the risk of reinjury when the athlete returns to play.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     LCL injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of the isolated lateral collateral ligament (LCL) injury is not clear. However, it appears that the majority do well with nonoperative treatment. The management of these injuries is as described for isolated MCL injuries. During phase one of treatment, bracing is not necessary for grade 1 and 2 injuries (stable with valgus testing). Grade 3 injuries are treated for four to six weeks with a hinged rehabilitative brace, set with a limit of 0 to 90 degrees of flexion initially, and then allowing increased flexion over time. Rehabilitation during phases two through four is as described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     PCL injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of isolated posterior cruciate ligament (PCL) injuries is not clear. Some athletes can return to play without restrictions; others have evidence of chronic instability. Patients without evidence of chronic instability can be managed nonoperatively. Injuries that occur in conjunction with an avulsion fracture, other ligament injuries, or meniscal injuries require surgery.",
"   </p>",
"   <p>",
"    During the initial phases of nonoperative management, routine bracing is not necessary. Quadriceps strengthening is a priority. Hamstring strengthening and open kinetic chain exercises should be avoided, because they promote posterior translation of the tibia. Hamstring curls are an example of an open chain hamstring-strengthening exercise that should be avoided until quadriceps strength is nearing normal. In open chain exercise, the distal aspect of the extremity is free to move, such as with knee extensions in the seated position, where the foot is moving as the knee is extending. In closed kinetic chain exercises, the distal extremity is fixed in position, such as squats in which the hip and knee flex but the foot does not move.",
"   </p>",
"   <p>",
"    Meniscal injury, damage to secondary restraints, or inadequate rehabilitation of the quadriceps and hamstring muscles should be considered before primary repair of the PCL is undertaken in patients who have symptoms of chronic instability (eg, shifting, pain, and effusion).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     ACL injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of ACL injuries is, in the majority of cases, characterized by evidence of chronic instability. Chronic instability is the indication for primary ACL repair. However, instability also can be caused by meniscal pathology and inadequately rehabilitated hamstring and quadriceps muscles (dynamic stabilizers). Athletes often can return to play at a less stressful level without surgical reconstruction if they undergo a complete rehabilitation program [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4056/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The type of stabilizing brace to be used for ACL injuries depends upon the treatment plan. The orthopedic surgeon should choose the brace for patients who are to undergo surgery. A derotational ACL-stabilizing brace should be used for patients in whom the ACL sprain is to be treated nonoperatively.",
"   </p>",
"   <p>",
"    The decision regarding conservative versus surgical therapy must be individualized. Factors to be considered include the type of injury, physiologic maturity, projected remaining growth, competitive level, and future plans of the athlete [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4056/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For college-bound or elite athletes, the standard of care for isolated ACL injuries, if the athlete is to remain competitive, is primary repair. However, there are examples of college and professional athletes with ACL injuries who returned to play without primary repair and performed at their preinjury level.",
"     </li>",
"     <li>",
"      ACL reconstructive surgery has been performed in skeletally immature patients (usually as they approached skeletal maturity), and a majority were able to return to sports participation [",
"      <a class=\"abstract\" href=\"UTD.htm?3/61/4056/abstract/14\">",
"       14",
"      </a>",
"      ]. The typical postoperative recovery and rehabilitation period is usually 9 to 12 months.",
"     </li>",
"     <li>",
"      For an isolated ACL injury (a minority of acute weightbearing injuries characterized by hemarthrosis), conservative management with rehabilitation and bracing for six months should be considered, particularly if the athlete is willing to reduce his or her activity. This option may be especially important for the high school athlete who is unlikely to play competitive sports in college and wants to play on a school team during his or her senior year, as the prolonged post-operative",
"      <span class=\"nowrap\">",
"       recovery/rehabilitation",
"      </span>",
"      period necessitates missing nine to twelve months of play. Primary repair should be recommended if the athlete continues to have symptoms of instability (eg, shifting, pain, and effusion) during the six-month rehabilitation period [",
"      <a class=\"abstract\" href=\"UTD.htm?3/61/4056/abstract/11,15\">",
"       11,15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Athletes should be given the option of conservative management. However, if symptoms of instability persist (eg, shifting, pain, and effusion) during or after rehabilitation, surgery should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4056/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During phases two and three of treatment for acute ACL injuries, hamstring strengthening and neuromuscular control are emphasized to reduce the likelihood of anterior translation of the tibia on the femur. Whereas the normal ratio of hamstring:quadriceps strength is 2:3, the goal for the ACL-injured knee is 1:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4056/abstract/10\">",
"     10",
"    </a>",
"    ]. Gastrocnemius strengthening also is emphasized. Gastrocnemius strength is increased by performing weightbearing toe-raises with the knees in full extension. These exercises initially are performed using body weight alone, and then with additional weights supported on the shoulders.",
"   </p>",
"   <p>",
"    Functional assessment of ACL rehabilitation with the one-legged hop for distance or the vertical one-legged hop can help when making the decision regarding return to play.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Meniscal tear",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of meniscal tears depends upon the clinical presentation. Those that prevent full extension of the knee (ie, a locked joint) or those that have persistent mechanical symptoms require surgery because they can cause abnormal wear in the articular cartilage and hasten joint degeneration.",
"   </p>",
"   <p>",
"    However, other meniscal tears are best treated conservatively. A diffusely degenerated meniscus or a tear that has a stable base and is without a large mobile fragment can become asymptomatic over four to six weeks with relative rest, analgesia, and pain-free exercise. Acute tears that are peripheral (with good blood supply), stable, and small (&lt;7 mm) are likely to heal with conservative management.",
"   </p>",
"   <p>",
"    During the first four to six weeks of conservative treatment, a rehabilitation brace limited to 0 to 90 degrees of knee flexion should be used. Conservative and post-operative management involves four to six weeks without weightbearing, during which flexion exercises are avoided (because they can impair meniscal healing). The non-weightbearing period is followed by a four- to six-week period of protected weightbearing. Continued use of the rehabilitation brace may provide support and promote relative rest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Patellar subluxation/dislocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once patellar dislocation has been reduced, the RICE principles can be applied as described above. The reduction of patellar dislocation is described separately. Patients who have pain with weightbearing should be provided with crutches (",
"    <a class=\"graphic graphic_table graphicRef63565 \" href=\"UTD.htm?8/56/9099\">",
"     table 1",
"    </a>",
"    ). They also should be provided with a knee sleeve brace with a lateral buttress to prevent lateral displacement of the patella. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24581?source=see_link\">",
"     \"Patellar dislocations in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CHRONIC INJURIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Patellofemoral injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patellofemoral injuries include patellofemoral dysfunction (PFD), patellar tendinitis, quadriceps tendinitis, Osgood-Schlatter disease, and Sinding-Larsen-Johannson syndrome. The use of knee braces or orthotics is not indicated during the initial phase of the treatment program, with the exception of Osgood-Schlatter disease (in which an Osgood-Schlatter pad, or a brace with a doughnut pad around the tibial tuberosity), is recommended. On the other hand, patellar mobilization and patellar taping may assist the recovery of recalcitrant cases. Patellar mobilization involves passively gliding the patella medially in an attempt to stretch the passive patellar stabilizers that may be promoting lateral tracking of the patella in the femoral groove. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12392?source=see_link\">",
"     \"Osgood-Schlatter disease (tibial tuberosity avulsion)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial rehabilitation of chronic patellofemoral injuries involves the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Quadriceps strengthening",
"     </li>",
"     <li>",
"      Improved quadriceps and hamstring flexibility",
"     </li>",
"     <li>",
"      Ice at least once daily",
"     </li>",
"     <li>",
"      Relative rest",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Every patient with a patellofemoral injury should work on quadriceps strength [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4056/abstract/17\">",
"     17",
"    </a>",
"    ]. Quadriceps strength at presentation is a predictor of outcome at seven years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4056/abstract/18\">",
"     18",
"    </a>",
"    ]. Quadriceps strength can be increased, initially, with 10 sets of 10 maximal quad sets (maximal contraction of the quadriceps with the knee in full extension) done throughout the day. Cycling is another method of improving quadriceps strength and endurance. Closed kinetic chain exercises, such as squats, can be used as rehabilitation progresses, as long as they are pain-free and the patient only flexes the knee to a maximum of 30 degrees (as patellofemoral joint reactive [PFJR] forces are greatest in closed kinetic chain exercises at full flexion) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4056/abstract/19\">",
"     19",
"    </a>",
"    ]. Maximum PFJR forces are to be avoided.",
"   </p>",
"   <p>",
"    Quadriceps and hamstring stretching is initiated at the outset of treatment, and is best done through developing a home education program. The correct technique should be demonstrated to the patient by a physical therapist at a separate appointment with the therapist. Simply providing the patient a handout with pictures of exercises, without being able to practice and demonstrate the correct technique, is less than optimal.",
"   </p>",
"   <p>",
"    In a later phase of rehabilitation, isotonic knee extension exercises such as squats or terminal knee extensions (in which the patient pushes against a plate) can be used to increase the strength of the quadriceps muscles.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Knee extension exercises create greater PFJR forces than the leg press exercise at 0 and 30 degrees of flexion. Therefore, the ROM during these exercises should be from full knee extension not to exceed 40 degrees of flexion [",
"      <a class=\"abstract\" href=\"UTD.htm?3/61/4056/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. In this way, as the force on the patellofemoral joint increases, the surface area across which the force can be distributed increases, effectively increasing the articular surface stress. Knee extension exercises in which the seated patient extends the knee with excess weight on the distal tibia should be avoided. In these exercises, the patellar surface contact area actually decreases as the force increases, creating excess PFJR force, which is to be avoided.",
"     </li>",
"     <li>",
"      In squatting, the contact area and pressure on the articular surface of the patella increase proportionately between 0 and 30 degrees of knee flexion. However, between 30 and 60 degrees of knee flexion, the forces increase considerably [",
"      <a class=\"abstract\" href=\"UTD.htm?3/61/4056/abstract/22\">",
"       22",
"      </a>",
"      ]. Exercises going beyond 40 degrees of flexion are likely to increase PFJR force and worsen symptoms, and thus should be avoided.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The athlete should be seen in follow-up three to four weeks after the initial visit. If the patient is improving, the regime is not changed, and progressively more functional rehabilitation, such as the walk-run program and figure-eight exercises, is allowed (",
"    <a class=\"graphic graphic_table graphicRef68511 \" href=\"UTD.htm?15/18/15660\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In patients who have failed to improve after three to four weeks despite adhering to relative rest and the home exercise program, additional interventions may be needed. The patient should be reevaluated with particular attention to the strength of the external hip rotators, strength of the iliotibial band (ITB), and excessive pronation or supination.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If pronation or supination is present, appropriate running shoes",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      orthotics should be recommended.",
"     </li>",
"     <li>",
"      Strengthening exercises should be recommended for patients who continue to have poor external hip rotator function, (the positive corkscrew sign), indicating weakness of the external rotators of the hip. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29223?source=see_link\">",
"       \"Approach to the young athlete with chronic knee pain or injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Strengthening exercises should be recommended for patients who have ITB deficits.",
"     </li>",
"     <li>",
"      Patellar mobilization and patellar taping may assist the recovery of recalcitrant cases [",
"      <a class=\"abstract\" href=\"UTD.htm?3/61/4056/abstract/23\">",
"       23",
"      </a>",
"      ]. Neoprene sleeves have been useful in refractory cases of PFD. The mechanism of their therapeutic benefit may involve proprioceptive feedback",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      warming of the other structures. Attention to deficits of the ITB should be explored.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     ITB syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of ITB syndrome follows the same principles as the treatment of patellofemoral injuries. However, the emphasis is on improving strength, flexibility, and endurance of the tensor fascia",
"    <span class=\"nowrap\">",
"     lata/ITB.",
"    </span>",
"    As with any overuse injury, it is important to consider kinetic chain and training errors, because if these are not corrected, it is likely the condition will recur.",
"   </p>",
"   <p>",
"    The kinetic chain errors can be detected by observing the technique in clinic (eg, watching the patient walk or run on a treadmill). The kinetic chain refers to the components of the axial or appendicular skeleton involved in load dissipation during a particular movement. As an example, for walking, the kinetic chain includes the foot, ankle, knee, hip, pelvis, and back.",
"   </p>",
"   <p>",
"    Training errors, in general, involve too high a volume of training or too rapid an increase in training volume. Training errors can be detected by obtaining an exercise history from the patient, with an emphasis on the details of the exercise program. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29223?source=see_link\">",
"     \"Approach to the young athlete with chronic knee pain or injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations are made regarding the treatment of knee injuries in the young athlete:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of knee injuries in the young athlete should be directed by a clinician with expertise in this area.",
"     </li>",
"     <li>",
"      Athletes who have acute knee injuries with obvious deformity, crepitus,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neurovascular compromise should have the knee immobilized as comfortably as possible and be transferred to an emergency department for an orthopedic surgery consultation.",
"     </li>",
"     <li>",
"      Athletes with acute hemarthrosis, but no obvious deformity, crepitus, or neurovascular compromise may be managed by initially without surgery by primary care sports clinicians.",
"     </li>",
"     <li>",
"      Acute knee injuries without deformity or neurovascular compromise can be treated initially with rest, ice, compression, and elevation (RICE).",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nonsteroidal anti-inflammatory medication should be used in the first five to seven days to decrease pain and prevent a pain-disuse-atrophy cycle.",
"     </li>",
"     <li>",
"      Appropriate therapy must involve a rehabilitation program; flexibility, strength, and endurance should be rehabilitated simultaneously. The maintenance of quadriceps strength is essential in the rehabilitation of all types of acute knee injury.",
"     </li>",
"     <li>",
"      The rehabilitation program should be initiated on the day of injury if it can be performed without pain or swelling; follow the principle of relative rest.",
"     </li>",
"     <li>",
"      The importance of relative rest cannot be overemphasized. Relative rest means that the patient can perform any movement or activity, as long as there is no pain or swelling during or within 24 hours of the activity.",
"     </li>",
"     <li>",
"      The exercise program should be demonstrated by a physical therapist or athletic trainer who can train the athlete to use the correct technique.",
"     </li>",
"     <li>",
"      Anatomic, training, and environmental factors that contribute to injury must be identified and modified as appropriate.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4056/abstract/1\">",
"      Stanitski CL. Pediatric and adolescent sports injuries. Clin Sports Med 1997; 16:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4056/abstract/2\">",
"      Matelic TM, Aronsson DD, Boyd DW Jr, LaMont RL. Acute hemarthrosis of the knee in children. Am J Sports Med 1995; 23:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4056/abstract/3\">",
"      V&auml;h&auml;sarja V, Kinnuen P, Serlo W. Arthroscopy of the acute traumatic knee in children. Prospective study of 138 cases. Acta Orthop Scand 1993; 64:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4056/abstract/4\">",
"      Eiskjaer S, Larsen ST, Schmidt MB. The significance of hemarthrosis of the knee in children. Arch Orthop Trauma Surg 1988; 107:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4056/abstract/5\">",
"      Simonsen O, Jensen J, Mouritsen P, Lauritzen J. The accuracy of clinical examination of injury of the knee joint. Injury 1984; 16:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4056/abstract/6\">",
"      Bomberg BC, McGinty JB. Acute hemarthrosis of the knee: indications for diagnostic arthroscopy. Arthroscopy 1990; 6:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4056/abstract/7\">",
"      Lee K, Siegel MJ, Lau DM, et al. Anterior cruciate ligament tears: MR imaging-based diagnosis in a pediatric population. Radiology 1999; 213:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4056/abstract/8\">",
"      Wessel LM, Scholz S, R&uuml;sch M. Characteristic pattern and management of intra-articular knee lesions in different pediatric age groups. J Pediatr Orthop 2001; 21:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4056/abstract/9\">",
"      Stanitski CL, Harvell JC, Fu F. Observations on acute knee hemarthrosis in children and adolescents. J Pediatr Orthop 1993; 13:506.",
"     </a>",
"    </li>",
"    <li>",
"     Zachazewski JE, Magee DJ, Quillen WS. Athletic Injuries and Rehabilitation, WB Saunders, Philadelphia 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4056/abstract/11\">",
"      Kocher MS, Micheli LJ, Zurakowski D, Luke A. Partial tears of the anterior cruciate ligament in children and adolescents. Am J Sports Med 2002; 30:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4056/abstract/12\">",
"      Iobst CA, Stanitski CL. Acute knee injuries. Clin Sports Med 2000; 19:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4056/abstract/13\">",
"      Stanitski CL. Anterior Cruciate Ligament Injury in the Skeletally Immature Patient: Diagnosis and Treatment. J Am Acad Orthop Surg 1995; 3:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4056/abstract/14\">",
"      McCarroll JR, Shelbourne KD, Porter DA, et al. Patellar tendon graft reconstruction for midsubstance anterior cruciate ligament rupture in junior high school athletes. An algorithm for management. Am J Sports Med 1994; 22:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4056/abstract/15\">",
"      Fehnel DJ, Johnson R. Anterior cruciate injuries in the skeletally immature athlete: a review of treatment outcomes. Sports Med 2000; 29:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4056/abstract/16\">",
"      Graf BK, Lange RH, Fujisaki CK, et al. Anterior cruciate ligament tears in skeletally immature patients: meniscal pathology at presentation and after attempted conservative treatment. Arthroscopy 1992; 8:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4056/abstract/17\">",
"      Kannus P, Niittym&auml;ki S. Which factors predict outcome in the nonoperative treatment of patellofemoral pain syndrome? A prospective follow-up study. Med Sci Sports Exerc 1994; 26:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4056/abstract/18\">",
"      Natri A, Kannus P, J&auml;rvinen M. Which factors predict the long-term outcome in chronic patellofemoral pain syndrome? A 7-yr prospective follow-up study. Med Sci Sports Exerc 1998; 30:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4056/abstract/19\">",
"      Escamilla RF, Fleisig GS, Zheng N, et al. Biomechanics of the knee during closed kinetic chain and open kinetic chain exercises. Med Sci Sports Exerc 1998; 30:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4056/abstract/20\">",
"      van Eijden TM, Kouwenhoven E, Verburg J, Weijs WA. A mathematical model of the patellofemoral joint. J Biomech 1986; 19:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4056/abstract/21\">",
"      Steinkamp LA, Dillingham MF, Markel MD, et al. Biomechanical considerations in patellofemoral joint rehabilitation. Am J Sports Med 1993; 21:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4056/abstract/22\">",
"      Huberti HH, Hayes WC. Patellofemoral contact pressures. The influence of q-angle and tendofemoral contact. J Bone Joint Surg Am 1984; 66:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4056/abstract/23\">",
"      McConnell, J. The management of chondromalacia patellae: A long term solution. Aust J Physiother 1986; 32:215.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6532 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-1AFF26D322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_61_4056=[""].join("\n");
var outline_f3_61_4056=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHASES OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Phase one",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - RICE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Analgesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Arthroscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Initial rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Phase two",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Phase three",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Phase four",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ACUTE INJURIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MCL injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      LCL injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PCL injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ACL injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Meniscal tear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Patellar subluxation/dislocation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CHRONIC INJURIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Patellofemoral injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      ITB syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6532\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6532|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/56/9099\" title=\"table 1\">",
"      Crutches instructions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/18/15660\" title=\"table 2\">",
"      Walk-run program",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=related_link\">",
"      Approach to the young athlete with acute knee pain or injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29223?source=related_link\">",
"      Approach to the young athlete with chronic knee pain or injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37768?source=related_link\">",
"      Complex regional pain syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12392?source=related_link\">",
"      Osgood-Schlatter disease (tibial tuberosity avulsion)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24581?source=related_link\">",
"      Patellar dislocations in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28455?source=related_link\">",
"      Traumatic causes of acute knee pain and injury in the young athlete",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_61_4057="Syphilis in pregnancy";
var content_f3_61_4057=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Syphilis in pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/61/4057/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/61/4057/contributors\">",
"     Errol R Norwitz, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/61/4057/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/61/4057/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/61/4057/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/61/4057/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/61/4057/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/61/4057/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syphilis is a systemic infection caused by the spirochete Treponema pallidum, which is of particular concern during pregnancy because of the risk of transplacental infection of the fetus. Congenital infection is associated with several adverse outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/1-7\">",
"     1-7",
"    </a>",
"    ], including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Perinatal death",
"     </li>",
"     <li>",
"      Premature delivery",
"     </li>",
"     <li>",
"      Low birth weight",
"     </li>",
"     <li>",
"      Congenital anomalies",
"     </li>",
"     <li>",
"      Active congenital syphilis in the neonate",
"     </li>",
"     <li>",
"      Long-term sequelae, such as deafness and neurologic impairment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis, treatment, and sequelae of syphilis complicating pregnancy will be reviewed here. The pathogenesis, diagnosis, and treatment of syphilis in children and nonpregnant adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12150?source=see_link\">",
"     \"Pathophysiology, transmission, and natural history of syphilis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/48/776?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of late syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syphilis is an infection that occurs in different stages over time in the absence of treatment. Early syphilis is often referred to as primary, secondary, and early latent syphilis. These are the stages of syphilis that typically occur within the first year after acquisition of the infection and are classically associated with sexual transmission.",
"   </p>",
"   <p>",
"    Latent syphilis is defined as asymptomatic infection, with positive serology and a negative physical examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=see_link\">",
"     \"Diagnostic testing for syphilis\"",
"    </a>",
"    .) When latent infection can be documented to have occurred within one year of the acquisition of the organism, it is termed early latent syphilis. If latent infection arises after one year or the time of initial infection cannot be determined, it is defined as late latent syphilis or latent syphilis of unknown duration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\", section on 'Latent syphilis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Late or tertiary syphilis refers to the stages of syphilis that occur after early (primary or secondary) or latent syphilis. It typically involves the central nervous system (CNS), cardiovascular system, or the skin and subcutaneous tissues. Late syphilis can arise as soon as one year after initial infection or up to 25 to 30 years later. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/48/776?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of late syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE AND EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of syphilis dropped precipitously after the discovery of penicillin in the 1940s and reached a nadir during the following decade. The number of cases of early syphilis has risen subsequently, particularly among injection drug users, individuals infected with the human immunodeficiency virus (HIV), and men who have sex with men. The syphilis rate among women increased from 1.1 cases per 100,000 females in 2007 to 1.5 cases per 100,000 females in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Syphilis occurs with equal frequency in men and women. Eighty percent of women with syphilis are in the reproductive age group, and thus are at risk of transmitting the infection to the fetus if they become pregnant [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/8\">",
"     8",
"    </a>",
"    ]. Risk factors associated with syphilis in pregnancy include lack of health insurance, poverty, sex worker, use of illicit drugs, infection with other sexually transmitted diseases, and living in an area of high syphilis morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/9\">",
"     9",
"    </a>",
"    ]. Additional associations and risk factors are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef50671 \" href=\"UTD.htm?2/30/2539\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all new syphilis infections are sexually acquired, except for cases resulting from vertical transmission (ie, infection acquired in utero or during delivery). Syphilis is transmissible during the early stages of disease (primary and secondary syphilis) with an efficiency of horizontal (sexual) transmission estimated at approximately 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sexual transmission requires exposure to open lesions in which organisms are present. The spirochetes pass from the lesion across intact mucous membranes or abraded skin into the new host. The incubation period varies from 10 to 90 days (average approximately three weeks); larger inocula shorten this incubation period [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12150?source=see_link\">",
"     \"Pathophysiology, transmission, and natural history of syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Untreated infections of up to four years duration have been associated with vertical transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each stage of syphilis has characteristic clinical features that are not altered by pregnancy (",
"    <a class=\"graphic graphic_table graphicRef79946 \" href=\"UTD.htm?31/28/32203\">",
"     table 2",
"    </a>",
"    ). A synopsis is provided below; a detailed discussion can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/48/776?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of late syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Primary syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first manifestation of syphilis is a papule, which is typically painless, at the site of inoculation. This soon ulcerates to produce the classic chancre(s) of primary syphilis, a 1 to 2 centimeter painless ulcer with a raised, indurated margin that may be genital or extragenital. The ulcer is associated with mild to moderate regional lymphadenopathy that is often bilateral. Chancres heal spontaneously within three to six weeks, even in the absence of treatment. The primary stage of syphilis is often missed in women because the lesion is on vaginal or cervical mucosa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Secondary syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary syphilis is a disseminated systemic process that begins six weeks to six months after the appearance of the chancre in approximately 25 percent of untreated patients. A generalized maculopapular skin rash involving the palms and soles and mucous membranes, but usually sparing the face, is characteristic of this stage of the infection. Generalized lymphadenopathy accompanies the skin rash. Additional clinical features include fever, pharyngitis, weight loss, and large genital lesions called condylomata lata. Although spirochetes can be found in the cerebrospinal fluid (CSF) of around 40 to 50 percent of patients with early syphilis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/1\">",
"     1",
"    </a>",
"    ], neurologic manifestations are rare. The rash of secondary syphilis typically resolves spontaneously within two to six weeks. Secondary syphilis is commonly the stage when women present to a health care provider.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Latent syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Latent disease is usually subclinical, although clinical relapses, particularly of lesions of secondary syphilis, may occur. Syphilis is rarely transmitted during the latent phase, with the exception of perinatal transmission during pregnancy. The risk of congenital syphilis is directly related to the stage of syphilis in the mother and the risk is extremely high for the first four years after maternal acquisition of infection when spirochetemia is common in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Tertiary syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tertiary syphilis occurs in approximately one-third of untreated patients, but is now rarely seen since most patients are treated either deliberately or inadvertently when receiving penicillin for other indications. Tertiary syphilis is characterized by slowly progressive signs and symptoms. Clinical manifestations include gumma formation, cardiovascular disease,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CNS changes (neurosyphilis) (",
"    <a class=\"graphic graphic_table graphicRef79946 \" href=\"UTD.htm?31/28/32203\">",
"     table 2",
"    </a>",
"    ). Such manifestations usually develop 5 to 20 years after the disease has become latent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MATERNAL SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The problems associated with syphilis in pregnancy can be almost completely eliminated by universal early antepartum screening and treatment with appropriate antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/14\">",
"     14",
"    </a>",
"    ]. In one study using worldwide data, 66 percent of adverse outcomes occurred in women who were not tested or were not treated for syphilis during antenatal care [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The US Centers for Disease Control and Prevention and many other global and national organizations recommend that all pregnant women be screened for syphilis at the first prenatal visit [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/5,9,15-18\">",
"     5,9,15-18",
"    </a>",
"    ]. The cost and morbidity associated with testing for syphilis are low and the benefit of detecting and treating the disease is high for both mother and child. The major harm of screening is the anxiety associated with a false positive result [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The screening test should be",
"    <strong>",
"     repeated",
"    </strong>",
"    during the third trimester (at 28 to 32 weeks) and again at delivery in women who are at high risk for syphilis (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Incidence and epidemiology'",
"    </a>",
"    above), live in areas of high syphilis morbidity, are previously untested, or had a positive screening test in the first trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/21\">",
"     21",
"    </a>",
"    ]. Women who deliver stillborns after 20 weeks should also be tested.",
"   </p>",
"   <p>",
"    Screening women for syphilis should be considered in nontraditional settings, such as drug treatment centers, prisons, emergency medicine departments, and outreach programs, at the time pregnancy is confirmed, given that many women infected with syphilis first present for obstetrical care at the time of delivery.",
"   </p>",
"   <p>",
"    Seropositive pregnant women should be considered actively infected unless an adequate treatment history is clearly documented",
"    <strong>",
"     and",
"    </strong>",
"    sequential antibody titers have declined.",
"   </p>",
"   <p>",
"    All pregnant women should be offered HIV counseling and screening using an opt-out approach [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/22\">",
"     22",
"    </a>",
"    ]. HIV testing is strongly recommended for those known to have a sexually transmitted disease (STD), such as syphilis, due to the high risk of coexistent disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=see_link&amp;anchor=H1276464#H1276464\">",
"     \"Initial prenatal assessment and patient education\", section on 'Human immunodeficiency virus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;T. pallidum cannot be cultured in the laboratory. Therefore, the diagnosis of syphilis relies upon direct visualization of the organism or, more commonly, upon serologic testing. Newer diagnostic techniques, such as polymerase chain reaction, are currently being developed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Direct visualization",
"    </span>",
"    &nbsp;&mdash;&nbsp;T. pallidum cannot be visualized by light microscopy, but can be seen using darkfield microscopy. Darkfield microscopy can identify spirochetes in lesions or body secretions, although this technique is generally limited to clinics that specialize in the diagnosis and treatment of STDs (",
"    <a class=\"graphic graphic_picture graphicRef56211 \" href=\"UTD.htm?27/58/28590\">",
"     picture 1",
"    </a>",
"    ). This technique should not be used for secretions collected from oro-pharyngeal lesions due the existence of other indistinguishable non-treponemal spirochetes in the mouth. Direct fluorescent antibody stains have largely replaced darkfield microscopy, but still require a fluorescent microscope and a skilled technician. Most state health departments have the capacity to perform this assessment on slides submitted by clinicians. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnostic testing for syphilis\", section on 'Darkfield microscopy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=see_link&amp;anchor=H9#H9\">",
"     \"Diagnostic testing for syphilis\", section on 'Direct fluorescent antibody testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Serologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development and course of the maternal antibody response to syphilis infection are illustrated in the figure (",
"    <a class=\"graphic graphic_figure graphicRef54477 \" href=\"UTD.htm?43/26/44448\">",
"     figure 1",
"    </a>",
"    ). Serologic testing is an indirect method of diagnosis since it relies upon a maternal humoral immune response to the infection. Thus, these tests have inherent limitations. Two types of serologic testing are available: specific treponemal and nontreponemal antibody tests.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treponemal antibody tests (eg, fluorescent treponemal antibody absorption [FTA-ABS] test, the microhemagglutination assay for antibodies to Treponema pallidum [MHA-TP], and the Treponema pallidum particle agglutination assay [TPPA]) are confirmatory tests that detect antibodies specifically directed at treponemal cellular components. These tests are sensitive and specific, but expensive and correlate poorly with disease activity, since they remain positive despite treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=see_link&amp;anchor=H6#H6\">",
"       \"Diagnostic testing for syphilis\", section on 'Treponemal tests'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nontreponemal antibody tests (eg, Venereal Disease Research Laboratory [VDRL] test and the Rapid Plasma Reagin [RPR] test) are performed on serum and used as the screening test for syphilis in most settings. Positive tests are usually reported as a titer of antibody and can be used to follow the response to treatment in many patients. These tests are relatively inexpensive, easy to perform, and can also be done on other body fluids, such as CSF. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=see_link&amp;anchor=H5#H5\">",
"       \"Diagnostic testing for syphilis\", section on 'Nontreponemal tests'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The usual testing algorithm is to screen with a nontreponemal test such as the VDRL; a reactive specimen is then confirmed as a true positive with a treponemal test such as the FTA-ABS. Some clinical laboratories have begun using treponemal tests for screening, usually enzyme&ndash;immunoassay (EIA) or chemiluminescence immunoassays [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/21,23\">",
"     21,23",
"    </a>",
"    ]. These tests will be positive in persons who have untreated or treated syphilis and may have a reduced positive predictive power in populations with a low prevalence. Patients with positive treponemal tests used for screening should have a standard nontreponemal test with titer (VDRL or RPR) to guide management [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/21\">",
"     21",
"    </a>",
"    ]. If the nontreponemal test is negative, then a different treponemal test should be performed to confirm the results of the initial treponemal test. If the second treponemal test is positive and there was no prior therapy, the patient should be treated for late latent syphilis; if the patient was previously treated, no further treatment is needed unless the sexual history suggests re-exposure. If the second treponemal test is negative, no further treatment or testing is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25328909\">",
"    <span class=\"h3\">",
"     False positives",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the treponemal test is negative in a patient at low risk of acute syphilis and with a low titer nontreponemal test, the positive (reactive) nontreponemal test can be considered a transient biologic false positive result due to pregnancy. Women with biological false positives attributed to pregnancy should undergo follow-up testing four to six weeks after delivery. If the nontreponemal test continues to be positive with a negative treponemal test, then additional work-up to determine the etiology of the positive test is needed. If both the nontreponemal and the treponemal tests are positive, the woman needs to be treated for syphilis and the infant evaluated and treated if indicated. False positive tests are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=see_link&amp;anchor=H13#H13\">",
"     \"Diagnostic testing for syphilis\", section on 'Testing algorithms'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=see_link&amp;anchor=H19#H19\">",
"     \"Diagnostic testing for syphilis\", section on 'False positive test results'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cerebrospinal fluid examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy alone is not an indication for lumbar puncture [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/21\">",
"     21",
"    </a>",
"    ]. CSF examination is essential if there is any clinical evidence to suggest neurosyphilis, such as cranial nerve dysfunction, meningitis, stroke, acute or chronic altered mental status, loss of vibration sense, auditory or ophthalmic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/21\">",
"     21",
"    </a>",
"    ]. The criteria for CSF examination to evaluate for neurosyphilis are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=see_link&amp;anchor=H26#H26\">",
"     \"Diagnostic testing for syphilis\", section on 'Diagnostic testing for neurosyphilis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PERINATAL TRANSMISSION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;T. pallidum readily crosses the placenta, thereby resulting in fetal infection. Transplacental transmission can occur at any gestational age. The frequency of vertical transmission increases as gestation advances, but the severity of fetal infection decreases with infection later in pregnancy. Pregnancies complicated by untreated syphilis early in pregnancy are at increased risk of several adverse outcomes, although approximately 20 percent of children born to mothers with untreated syphilis will be normal [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intrauterine growth restriction",
"     </li>",
"     <li>",
"      Stillbirth",
"     </li>",
"     <li>",
"      Neonatal death",
"     </li>",
"     <li>",
"      Preterm birth",
"     </li>",
"     <li>",
"      Congenital infection and anomalies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Late transmission can result in many delayed manifestations, which can be subtle. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/11/37049?source=see_link\">",
"     \"Congenital syphilis: Evaluation, management, and prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17914?source=see_link&amp;anchor=H28809272#H28809272\">",
"     \"Congenital syphilis: Clinical features and diagnosis\", section on 'Early congenital syphilis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vertical transmission can occur at any stage of the disease. Perinatal transmission occurs in 50 percent of patients with primary or secondary syphilis, with fewer congenital infections among women with early latent (40 percent), late latent (10 percent), and tertiary disease (10 percent).",
"   </p>",
"   <p>",
"    Treatment of early maternal syphilis at least 30 days before delivery is the most important factor influencing the risk of congenital infection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/5\">",
"     5",
"    </a>",
"    ]. Seventy to 100 percent of infants born to untreated mothers will be infected compared to 1 to 2 percent of those born to women adequately treated during pregnancy. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Maternal treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An observational series of 43 treatment failures found the following characteristics were more likely in adequately treated women who went on to have congenitally infected infants: high VDRL titer at treatment and delivery, delivery &le;36 weeks, early stage of disease (secondary or early latent), and short interval between treatment and delivery (&le;30 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/24\">",
"     24",
"    </a>",
"    ]. The authors hypothesized that high treponemal load, altered penicillin pharmacokinetics in pregnancy, and inadequate time for fetal therapeutic response may have accounted for the treatment failures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Congenital syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of congenital syphilis corresponds to the incidence of disease in women. Most congenital cases are due to lack of prenatal care or late entry into prenatal care, but a negative test result in early pregnancy that was not repeated later in pregnancy in a high risk woman and suboptimal maternal treatment are also important contributing factors [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/19,25\">",
"     19,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Centers for Disease Control and Prevention (CDC) reported that the incidence of congenital syphilis in the United States increased in 2008, after a period of decline (10.1 cases per 100,000 live-born infants in 2008 [431 cases] versus 8.2 cases per 100,000 live-born infants in 2005 [339 cases]) in association with a 38 percent increase in the incidence of primary and secondary syphilis from 2004 to 2007 in women [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/5\">",
"     5",
"    </a>",
"    ]. Infants of black, Hispanic, and white mothers accounted for 50, 31, and 15 percent of cases, respectively. In about 75 percent of cases, the mother was not treated or was inadequately treated; many of these women had no documented prenatal care. In a smaller proportion of cases (16 percent), the mother was adequately treated, but did not have an adequate serologic response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Placenta",
"    </span>",
"    &nbsp;&mdash;&nbsp;The placenta is typically large and edematous. Characteristic placental findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hydrops placentalis",
"     </li>",
"     <li>",
"      Chronic villitis (plasma cells, mixed acute and chronic infiltrate)",
"     </li>",
"     <li>",
"      Perivillous fibrous proliferation (onion skin vessels)",
"     </li>",
"     <li>",
"      Normoblastemia",
"     </li>",
"     <li>",
"      Necrotizing funisitis",
"     </li>",
"     <li>",
"      Acute chorioamnionitis",
"     </li>",
"     <li>",
"      Plasma cell deciduitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Fetus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Damage to the fetus depends upon its stage of development at the time of infection and the duration of untreated infection. In the absence of therapy, fetal infections acquired early in pregnancy can result in miscarriage, stillbirth, growth restriction, hydrops fetalis, premature delivery, and neonatal death [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fetal infection is initially characterized by placental involvement and hepatic dysfunction (eg, abnormal aspartate aminotransferase or gamma-glutamyl transpeptidase), followed by amniotic fluid infection, hematologic abnormalities, ascites, and hydrops [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/26\">",
"     26",
"    </a>",
"    ]. One series of 24 gravida with primary, secondary, or early latent syphilis diagnosed after 24 weeks of gestation reported 66 percent of fetuses had either congenital syphilis or T. pallidum detected in amniotic fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/26\">",
"     26",
"    </a>",
"    ]. The types of, and numbers with, fetal abnormalities were: abnormal liver function tests (21), hepatomegaly (16), thrombocytopenia (8), anemia (6), ascites (3), and positive fetal antitreponemal IgM (3). Treatment failure occurred in three patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Infant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations, diagnosis, treatment, and prognosis of congenital syphilis in the neonate are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/11/37049?source=see_link\">",
"     \"Congenital syphilis: Evaluation, management, and prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17914?source=see_link\">",
"     \"Congenital syphilis: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     MATERNAL TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penicillin is the gold standard for the treatment of syphilis in both pregnant and nonpregnant individuals. No clinically-relevant penicillin-resistant strains of T. pallidum have been identified to date. Penicillin therapy in pregnancy is effective for treating maternal disease, preventing transmission to the fetus, and treating established fetal disease. Pregnant women with syphilis should be treated with the appropriate penicillin regimen according to their stage of disease (",
"    <a class=\"graphic graphic_table graphicRef79645 \" href=\"UTD.htm?21/56/22412\">",
"     table 3",
"    </a>",
"    ), including those who:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Have a history of sexual contact with a person with documented syphilis",
"     </li>",
"     <li>",
"      Display evidence of spirochetes on darkfield microscopy",
"     </li>",
"     <li>",
"      Show serologic evidence of syphilis with confirmation by a specific treponemal test",
"     </li>",
"     <li>",
"      Have been treated previously for syphilis, but have persistently elevated (&ge;1:4) or rising titers by VDRL or RPR",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A single dose of benzathine penicillin therapy for early disease is only appropriate when it is possible to document that there was a nonreactive syphilis serology within the past year or if there is good documentation of the chance of primary syphilis within the past year. Some authorities, the author included, suggest that a second dose of benzathine penicillin be given one week after the first to improve the likelihood of a serologic response in early disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In all other cases, the disease should be considered latent syphilis of unknown duration for which three doses of benzathine penicillin at weekly intervals are recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/48/776?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of late syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Penicillin allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious allergic reactions to penicillin are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/28\">",
"     28",
"    </a>",
"    ]. Nonpregnant women with a history of penicillin allergy may be treated with alternative antibiotics. However, during pregnancy, such regimens are either ineffective (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ), contraindicated (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ), lack sufficient data regarding efficacy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ), or are considered inappropriate because of reports of treatment failure (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ); therefore, they are",
"    <strong>",
"     not",
"    </strong>",
"    recommended. The",
"    <strong>",
"     only",
"    </strong>",
"    satisfactory treatment for penicillin-allergic pregnant patients with syphilis is desensitization followed by penicillin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link&amp;anchor=H1969477#H1969477\">",
"     \"Allergy to penicillins\", section on 'Desensitization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A small study in China evaluated the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    for treatment of early syphilis in 11 pregnant women with a history of penicillin allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/29\">",
"     29",
"    </a>",
"    ]. Preliminary results were encouraging, RPR titers fell and there were no clinical manifestations of congenital syphilis in the infants. A large scale trial of this treatment strategy is planned as an alternative to desensitization. Until the results of such trials are available, penicillin desensitization followed by penicillin treatment should be regarded as \"standard of care\" for the management of penicillin-allergic women with syphilis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Skin testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penicillin allergy is reported by 5 to 10 percent of pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/30\">",
"     30",
"    </a>",
"    ]. Skin testing to document a true penicillin allergy should be performed in all such women, except those who have had a documented anaphylactic reaction to penicillin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20600?source=see_link\">",
"     \"Penicillin skin testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link&amp;anchor=H1968768#H1968768\">",
"     \"Allergy to penicillins\", section on 'Penicillin skin testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to verify the history of \"allergy,\" since the patient may incorrectly assume a nonallergic side effect (eg, nausea or vomiting) to be allergic in origin (",
"    <a class=\"graphic graphic_table graphicRef71375 \" href=\"UTD.htm?13/23/13692\">",
"     table 4",
"    </a>",
"    ). As an example, a study performed by the Penicillin Study Group found that in patients with an invalid history of self-reported penicillin allergy or reaction, the reaction rate upon skin testing was 0 percent. When the history was \"questionable,\" 6 percent reacted to skin tests. Twelve percent of those with a history considered valid reacted to skin testing [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major concern is IgE mediated responses, as indicated by urticaria, angioedema or anaphylaxis with airway obstruction, bronchospasm or hypotension. Patients with a history of a severe allergic reaction to penicillin can be tested with major and minor determinants to identify those at high risk [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with a positive skin test are at significant risk of a reaction to penicillin; two-thirds develop some allergic symptoms and a subset of those will have a life-threatening anaphylactic reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/30\">",
"     30",
"    </a>",
"    ]. Penicillin desensitization is recommended for women with a positive skin test who require penicillin therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link&amp;anchor=H1969477#H1969477\">",
"     \"Allergy to penicillins\", section on 'Desensitization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Desensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penicillin desensitization involves exposing the patient to a small amount of penicillin and gradually increasing the dose until an effective level is reached, followed by the appropriate therapeutic penicillin regimen. Penicillin desensitization can be achieved either orally or intravenously. Oral desensitization is simpler and safer. The procedure requires approximately four hours to accomplish and requires close patient monitoring. Most adverse reactions can be managed without discontinuation of the desensitization protocol.",
"   </p>",
"   <p>",
"    Consultation with an allergist or other provider experienced in drug desensitization is strongly recommended to assist in guiding the management of such patients. Protocols for intravenous desensitizations are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link&amp;anchor=H1969477#H1969477\">",
"     \"Allergy to penicillins\", section on 'Desensitization'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=see_link\">",
"     \"Rapid drug desensitization for immediate hypersensitivity reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4310673\">",
"    <span class=\"h2\">",
"     Jarisch-Herxheimer reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of syphilis may precipitate the Jarisch-Herxheimer reaction, an acute febrile reaction accompanied by headache, myalgia, rash, and hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/34\">",
"     34",
"    </a>",
"    ]. These symptoms are thought to result from the release of large amounts of treponemal lipopolysaccharide from dying spirochetes and an increase in circulating cytokine levels (tumor necrosis factor alpha (TNF-alpha), interleukin-6, interleukin-8).",
"   </p>",
"   <p>",
"    The reaction begins within one to two hours of treatment, peaks at eight hours, and typically resolves within 24 to 48 hours. In one series,",
"    <span class=\"nowrap\">",
"     15/33",
"    </span>",
"    pregnant women treated for syphilis had a Jarisch-Herxheimer reaction, including",
"    <span class=\"nowrap\">",
"     3/3",
"    </span>",
"    with primary syphilis,",
"    <span class=\"nowrap\">",
"     12/20",
"    </span>",
"    with secondary syphilis, and",
"    <span class=\"nowrap\">",
"     0/10",
"    </span>",
"    with latent syphilis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/34\">",
"     34",
"    </a>",
"    ]. The reaction may be more common in HIV-positive women. All patients should be counseled about the risks and clinical features of this febrile reaction and providers should consider observing the patient for one to two hours before she leaves the outpatient facility. Management is supportive care (eg, antipyretics, intravenous fluids).",
"   </p>",
"   <p>",
"    The Jarisch-Herxheimer reaction may precipitate uterine contractions, preterm labor,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nonreassuring fetal heart rate tracings in pregnant women treated in the second half of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/35\">",
"     35",
"    </a>",
"    ]. Women should be told to report symptoms of labor or decreased fetal activity; evaluation and treatment are according to usual obstetric standards. The risk of occurrence of Jarisch-Herxheimer reaction is not a contraindication to syphilis treatment.",
"   </p>",
"   <p>",
"    Premedication with TNF-a antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/36,37\">",
"     36,37",
"    </a>",
"    ] or corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/38\">",
"     38",
"    </a>",
"    ] appears to prevent the reaction, but is not widely used given limited data of the relative risks and benefits of this approach, particularly in pregnant women.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one randomized trial, 49 patients with relapsing fever were randomly assigned to receive either 0.25 g of specific anti&ndash;TNF",
"      <em>",
"       -",
"      </em>",
"      alpha",
"      <em>",
"      </em>",
"      Fab or placebo before penicillin injection [",
"      <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/36\">",
"       36",
"      </a>",
"      ]. Clinically evident Jarisch&ndash;Herxheimer reactions occurred in",
"      <span class=\"nowrap\">",
"       26/29",
"      </span>",
"      control patients versus",
"      <span class=\"nowrap\">",
"       10/20",
"      </span>",
"      patients given anti&ndash;TNF-alpha Fab (90 versus 50 percent, P = 0.006).",
"     </li>",
"     <li>",
"      In another study of 22 patients with primary syphilis treated with penicillin for three days, 15 patients were given penicillin alone while another 17 received 20, 40, or 60 mg of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      on the first and second day of antibiotic administration [",
"      <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/38\">",
"       38",
"      </a>",
"      ]. Jarisch&ndash;Herxheimer reactions (defined as temperature &ge;38 degrees Celsius) occurred more frequently in the control group (93 verus 12 percent) and in no patient who received 60 mg of prednisolone. Nonfebrile manifestations of the reaction were not evaluated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Premedication with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or meptazinol may reduce the severity or duration of symptoms, but the reaction itself is not prevented [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/39\">",
"     39",
"    </a>",
"    ]; premedication with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    has not been effective [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Following titers after treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nontreponemal antibody serologic titers should be checked at 1, 3, 6, 12, and 24 months following treatment; the same type of nontreponemal test should be used before and after treatment to optimize comparison of results. Titers should decrease four-fold by six months post therapy and become nonreactive by 12 to 24 months.",
"   </p>",
"   <p>",
"    Titers that rise (a fourfold rise is diagnostic) or do not decrease appropriately suggest either treatment failure or reinfection. The treatment regimen should be repeated in these cases. Consideration should also be given to performing a lumbar puncture to evaluate for CNS involvement.",
"   </p>",
"   <p>",
"    Laboratory follow-up after treatment of syphilis is the same in pregnant and nonpregnant women and is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18837?source=see_link\">",
"     \"Laboratory monitoring of patients undergoing treatment for syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H638515\">",
"    <span class=\"h1\">",
"     OBSTETRICAL ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A fetal ultrasound should be obtained if maternal syphilis is diagnosed after 20 weeks of gestation to look for signs of congenital infection. Ultrasonographic signs of fetal syphilis (eg, hydrops fetalis, hepatosplenomegaly), if present, should be managed in conjunction with obstetric and infectious disease specialists because of the higher risk of fetal treatment failure [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4057/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=see_link\">",
"     \"Nonimmune hydrops fetalis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As discussed above, maternal treatment can provoke pregnancy complications. (See",
"    <a class=\"local\" href=\"#H4310673\">",
"     'Jarisch-Herxheimer reaction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/37/27217?source=see_link\">",
"       \"Patient information: Congenital syphilis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syphilis remains an important health concern for women, especially HIV-infected women, despite the availability of effective and inexpensive treatment. Failure to detect or adequately treat maternal disease often results in serious sequelae for the fetus and neonate. Penicillin remains the gold standard for the treatment of syphilis in both pregnant and nonpregnant patients. Penicillin desensitization is indicated for infected pregnant women with documented penicillin allergy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Each stage of syphilis has characteristic clinical features that are not altered by pregnancy (",
"      <a class=\"graphic graphic_table graphicRef79946 \" href=\"UTD.htm?31/28/32203\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All pregnant women should be screened for syphilis at the first prenatal visit (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The screening test should be",
"      <strong>",
"       repeated",
"      </strong>",
"      during the third trimester (28 to 32 weeks of gestation) and again at delivery in women who are at high risk for syphilis, live in areas with high prevalence of syphilis, are previously untested, or had a positive screening test in the first trimester. Women who deliver stillborns after 20 weeks should also be tested, as well as women in nontraditional settings who may not present for prenatal care until delivery. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Maternal screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vertical transmission of syphilis can occur at any time during pregnancy and at any stage of the disease. Treatment of maternal syphilis reduced the risk of congenital infection. Treatment of early maternal syphilis at least 30 days before delivery is the most important factor influencing the risk of congenital infection. The diagnosis of congenital syphilis requires a high index of clinical suspicion and confirmatory microscopic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      serologic testing. Cord blood screening alone is not reliable, as false negatives occur if the maternal titer is low or the mother was infected late in pregnancy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Perinatal transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Penicillin therapy is effective for treating maternal disease, preventing transmission to the fetus, and treating established fetal disease. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Maternal treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that pregnant women with syphilis be treated with the appropriate penicillin regimen according to their stage of disease (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Maternal treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that penicillin-allergic pregnant patients with syphilis undergo desensitization followed by penicillin therapy, given that alternative drugs are not as safe and effective in pregnancy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Penicillin allergy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of syphilis may precipitate the Jarisch-Herxheimer reaction, which may precipitate uterine contractions, preterm labor,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nonreassuring fetal heart rate tracing in pregnant women treated in the second half of pregnancy. We suggest supportive care of maternal discomfort and standard obstetrical management of pregnancy complications (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4310673\">",
"       'Jarisch-Herxheimer reaction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nontreponemal antibody serologic titers are checked at 1, 3, 6, 12, and 24 months following treatment and should decrease four-fold by six months post-therapy and become nonreactive by 12 to 24 months. If titers show a four-fold rise or do not decrease appropriately, then treatment failure or reinfection is likely. We recommend retreatment of these women (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Following titers after treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/1\">",
"      Ray JG. Lues-lues: maternal and fetal considerations of syphilis. Obstet Gynecol Surv 1995; 50:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/2\">",
"      FIUMARA NJ, FLEMING WL, DOWNING JG, GOOD FL. The incidence of prenatal syphilis at the Boston City Hospital. N Engl J Med 1952; 247:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/3\">",
"      Ricci JM, Fojaco RM, O'Sullivan MJ. Congenital syphilis: the University of Miami/Jackson Memorial Medical Center experience, 1986-1988. Obstet Gynecol 1989; 74:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/4\">",
"      FIUMARA NJ. Congenital syphilis in Massachusetts. N Engl J Med 1951; 245:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/5\">",
"      Centers for Disease Control and Prevention (CDC). Congenital syphilis - United States, 2003-2008. MMWR Morb Mortal Wkly Rep 2010; 59:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/6\">",
"      Watson-Jones D, Changalucha J, Gumodoka B, et al. Syphilis in pregnancy in Tanzania. I. Impact of maternal syphilis on outcome of pregnancy. J Infect Dis 2002; 186:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/7\">",
"      Newman L, Kamb M, Hawkes S, et al. Global estimates of syphilis in pregnancy and associated adverse outcomes: analysis of multinational antenatal surveillance data. PLoS Med 2013; 10:e1001396.",
"     </a>",
"    </li>",
"    <li>",
"     www.cdc.gov/std/stats08/tables/33.htm (accessed April 20, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/9\">",
"      U.S. Preventive Services Task Force. Screening for syphilis infection in pregnancy: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2009; 150:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/10\">",
"      ROCKWELL DH, YOBS AR, MOORE MB Jr. THE TUSKEGEE STUDY OF UNTREATED SYPHILIS; THE 30TH YEAR OF OBSERVATION. Arch Intern Med 1964; 114:792.",
"     </a>",
"    </li>",
"    <li>",
"     Sparling PF. Natural history of syphilis. In: Sexually Transmitted Diseases, Holmes KK, Mardh PA, Sparling PF, et al (Eds), McGraw-Hill, New York 1990. p.213.",
"    </li>",
"    <li>",
"     Harmon, N. Staying the Plague, London, 1917.",
"    </li>",
"    <li>",
"     Ingraham, NR. The value of penicillin alone in the prevention and treatment of congenital syphilis. Acto Derm Venereol (Stockh) 1951; 31.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/14\">",
"      Cheng JQ, Zhou H, Hong FC, et al. Syphilis screening and intervention in 500,000 pregnant women in Shenzhen, the People's Republic of China. Sex Transm Infect 2007; 83:347.",
"     </a>",
"    </li>",
"    <li>",
"     National Evidence-Based Clinical Guidelines. Antenatal care: routine care for the healthy pregnant woman. www.rcog.org.uk/index.asp?PageID=693 (accessed March 28, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/16\">",
"      Hossain M, Broutet N, Hawkes S. The elimination of congenital syphilis: a comparison of the proposed World Health Organization action plan for the elimination of congenital syphilis with existing national maternal and congenital syphilis policies. Sex Transm Dis 2007; 34:S22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/17\">",
"      Wolff T, Shelton E, Sessions C, Miller T. Screening for syphilis infection in pregnant women: evidence for the U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2009; 150:710.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists and American Academy of Pediatrics. Guidelines for Perinatal Care, 7th edition, 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/19\">",
"      Geusau A, Kittler H, Hein U, et al. Biological false-positive tests comprise a high proportion of Venereal Disease Research Laboratory reactions in an analysis of 300,000 sera. Int J STD AIDS 2005; 16:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/20\">",
"      Tinajeros F, Grossman D, Richmond K, et al. Diagnostic accuracy of a point-of-care syphilis test when used among pregnant women in Bolivia. Sex Transm Infect 2006; 82 Suppl 5:v17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/21\">",
"      Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/22\">",
"      ACOG Committee on Obstetric Practice. ACOG committee opinion number 304, November 2004. Prenatal and perinatal human immunodeficiency virus testing: expanded recommendations. Obstet Gynecol 2004; 104:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/23\">",
"      Centers for Disease Control and Prevention (CDC). Syphilis testing algorithms using treponemal tests for initial screening--four laboratories, New York City, 2005-2006. MMWR Morb Mortal Wkly Rep 2008; 57:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/24\">",
"      Sheffield JS, S&aacute;nchez PJ, Morris G, et al. Congenital syphilis after maternal treatment for syphilis during pregnancy. Am J Obstet Gynecol 2002; 186:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/25\">",
"      Mascola L, Pelosi R, Blount JH, et al. Congenital syphilis. Why is it still occurring? JAMA 1984; 252:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/26\">",
"      Hollier LM, Harstad TW, Sanchez PJ, et al. Fetal syphilis: clinical and laboratory characteristics. Obstet Gynecol 2001; 97:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/27\">",
"      Wendel GD Jr, Sheffield JS, Hollier LM, et al. Treatment of syphilis in pregnancy and prevention of congenital syphilis. Clin Infect Dis 2002; 35:S200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/28\">",
"      Johannes CB, Ziyadeh N, Seeger JD, et al. Incidence of allergic reactions associated with antibacterial use in a large, managed care organisation. Drug Saf 2007; 30:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/29\">",
"      Zhou P, Gu Z, Xu J, et al. A study evaluating ceftriaxone as a treatment agent for primary and secondary syphilis in pregnancy. Sex Transm Dis 2005; 32:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/30\">",
"      Wendel GD Jr, Stark BJ, Jamison RB, et al. Penicillin allergy and desensitization in serious infections during pregnancy. N Engl J Med 1985; 312:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/31\">",
"      Green GR, Rosenblum AH, Sweet LC. Evaluation of penicillin hypersensitivity: value of clinical history and skin testing with penicilloyl-polylysine and penicillin G. A cooperative prospective study of the penicillin study group of the American Academy of Allergy. J Allergy Clin Immunol 1977; 60:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/32\">",
"      Saxon A, Beall GN, Rohr AS, Adelman DC. Immediate hypersensitivity reactions to beta-lactam antibiotics. Ann Intern Med 1987; 107:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/33\">",
"      Yates AB. Management of patients with a history of allergy to beta-lactam antibiotics. Am J Med 2008; 121:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/34\">",
"      Klein VR, Cox SM, Mitchell MD, Wendel GD Jr. The Jarisch-Herxheimer reaction complicating syphilotherapy in pregnancy. Obstet Gynecol 1990; 75:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/35\">",
"      Myles TD, Elam G, Park-Hwang E, Nguyen T. The Jarisch-Herxheimer reaction and fetal monitoring changes in pregnant women treated for syphilis. Obstet Gynecol 1998; 92:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/36\">",
"      Fekade D, Knox K, Hussein K, et al. Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha. N Engl J Med 1996; 335:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/37\">",
"      Coxon RE, Fekade D, Knox K, et al. The effect of antibody against TNF alpha on cytokine response in Jarisch-Herxheimer reactions of louse-borne relapsing fever. QJM 1997; 90:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/38\">",
"      Gudj&oacute;nsson H, Skog E. The effect of prednisolone on the Jarisch-Herxheimer reaction. Acta Derm Venereol 1968; 48:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/39\">",
"      Pound MW, May DB. Proposed mechanisms and preventative options of Jarisch-Herxheimer reactions. J Clin Pharm Ther 2005; 30:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4057/abstract/40\">",
"      Remick DG, Negussie Y, Fekade D, Griffin G. Pentoxifylline fails to prevent the Jarisch-Herxheimer reaction or associated cytokine release. J Infect Dis 1996; 174:627.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4794 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-B60670ABF6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_61_4057=[""].join("\n");
var outline_f3_61_4057=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE AND EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Primary syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Secondary syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Latent syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Tertiary syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MATERNAL SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Direct visualization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Serologic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25328909\">",
"      - False positives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cerebrospinal fluid examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PERINATAL TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Congenital syphilis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Placenta",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Fetus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MATERNAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Penicillin allergy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Skin testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Desensitization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4310673\">",
"      Jarisch-Herxheimer reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Following titers after treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H638515\">",
"      OBSTETRICAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4794\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4794|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/26/44448\" title=\"figure 1\">",
"      Antibody development syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4794|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/58/28590\" title=\"picture 1\">",
"      Darkfield Treponema pallidum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4794|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/30/2539\" title=\"table 1\">",
"      Risk factors syphilis pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/28/32203\" title=\"table 2\">",
"      Clinical features of syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/56/22412\" title=\"table 3\">",
"      Treatment syphilis in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/23/13692\" title=\"table 4\">",
"      Types of allergic reactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17914?source=related_link\">",
"      Congenital syphilis: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/11/37049?source=related_link\">",
"      Congenital syphilis: Evaluation, management, and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=related_link\">",
"      Diagnostic testing for syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=related_link\">",
"      Initial prenatal assessment and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18837?source=related_link\">",
"      Laboratory monitoring of patients undergoing treatment for syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=related_link\">",
"      Nonimmune hydrops fetalis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of early syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/48/776?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of late syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12150?source=related_link\">",
"      Pathophysiology, transmission, and natural history of syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/37/27217?source=related_link\">",
"      Patient information: Congenital syphilis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20600?source=related_link\">",
"      Penicillin skin testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=related_link\">",
"      Rapid drug desensitization for immediate hypersensitivity reactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_61_4058="Prognosis of heart failure";
var content_f3_61_4058=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prognosis of heart failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/61/4058/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/61/4058/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/61/4058/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/61/4058/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/61/4058/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/61/4058/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/61/4058/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aging of the population and prolongation of the lives of cardiac patients by modern therapeutic innovations has led to an increasing incidence of heart failure (HF). Despite improvements in therapy, the mortality rate in patients with HF has remained unacceptably high [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15497?source=see_link\">",
"     \"Epidemiology and causes of heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prognosis of patients with HF will be reviewed here. The many factors that can be used to predict survival and the prognosis in patients with asymptomatic left ventricular systolic or diastolic dysfunction are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=see_link\">",
"     \"Predictors of survival in heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28601?source=see_link\">",
"     \"Evaluation and management of asymptomatic left ventricular systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STAGES OF HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure is often a progressive condition, beginning with predisposing factors and leading to the development and worsening of clinical illness. There are several stages in the evolution of HF, as outlined by an",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    task force [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage A &mdash; High risk for HF, without structural heart disease or symptoms",
"     </li>",
"     <li>",
"      Stage B &mdash; Heart disease with asymptomatic left ventricular dysfunction",
"     </li>",
"     <li>",
"      Stage C &mdash; Prior or current symptoms of HF",
"     </li>",
"     <li>",
"      Stage D &mdash; Refractory end stage HF",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This staged system emphasizes the progressive nature of HF and defines the appropriate therapeutic approach for each stage (",
"    <a class=\"graphic graphic_algorithm graphicRef57809 \" href=\"UTD.htm?1/38/1637\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HOSPITALIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for hospitalization is an important marker for poor prognosis. The association of nonfatal hospitalization and subsequent mortality rates was studied using data on 7572 chronic HF patients with reduced or preserved LVEF in the CHARM trials [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/3\">",
"     3",
"    </a>",
"    ]. Mortality rate was increased after HF hospitalizations, even after adjustment for baseline predictors of death (HR 3.2; 95% CI 2.8-3.5). The increased risk of death was highest within one month of discharge and declined progressively over time.",
"   </p>",
"   <p>",
"    There is an appreciable readmission rate for decompensated HF and patients hospitalized longer or more frequently have a higher mortality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. In a review of elderly patients, for example, 8 percent required readmission for HF within six months of the initial hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Poor compliance is an important contributing factor in many patients requiring readmission [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. In one series, lack of adherence to the medical program (drug or diet) was the most common reason for readmission, occurring in 41 percent of cases; another 12 percent received inadequate preadmission treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/4\">",
"     4",
"    </a>",
"    ]. It has been estimated that more than one-half of readmissions are preventable [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The roles of drug and device therapy in reducing hospitalization in patients with systolic HF, the impact of drug therapy on hospitalization in patients with diastolic HF, and the use of disease management and other strategies to reduce hospitalization in patients with HF are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37929?source=see_link\">",
"     \"Strategies to reduce hospitalizations in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SURVIVAL IN HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morbidity and mortality after the onset of symptomatic HF is extremely high, although variable mortality rates have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/9-15\">",
"     9-15",
"    </a>",
"    ], which in part reflect differences in disease severity and in appropriate medical therapy. The following statistics refer to patients with systolic HF, since the natural history of diastolic dysfunction is less well defined (see",
"    <a class=\"local\" href=\"#H26\">",
"     'Diastolic dysfunction'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     In-hospital mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients hospitalized for HF, in-hospital mortality and length of hospital stay have decreased, despite an increase in the severity of HF [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. As an example, a single-center study of 6676 patients hospitalized for HF found that, over a 10 year period (1986 to 1996), there was reduction in observed in-hospital mortality from 8.4 to 6.1 percent (despite slight increase in predicted mortality) and reduction in adjusted length of hospital stay from 7.7 to 5.6 days [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, reductions in in-hospital mortality have been accompanied by lesser [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/17\">",
"     17",
"    </a>",
"    ] or no decrease in 30-day mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/18\">",
"     18",
"    </a>",
"    ]. An analysis of 2,540,838 Medicare beneficiaries hospitalized with HF between 2001 and December 2005 revealed reduction in observed in-hospital mortality from 5.1 to 4.2 percent although 30 day mortality was unchanged at 11 percent. Nearly one in four patients was readmitted within 30 days of the index hospitalization.",
"   </p>",
"   <p>",
"    The 30-day mortality data demonstrate that the use of in-hospital mortality alone in evaluating HF prognosis can be misleading, especially when the length of hospital stay is declining and readmission rates are high. They also raise the concern that reduction in the length of stay after hospitalization for HF has had adverse consequences, possibly increasing early post-discharge mortality because a greater number of patients are discharged in an unstable condition. However, it is also possible that in the later years of the studies more terminally ill patients were being discharged from the hospital to die in other settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Long-term mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term mortality rates for patients with HF have improved over time [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/17,19,20\">",
"     17,19,20",
"    </a>",
"    ], although later studies indicate a slower rate of improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/18,21\">",
"     18,21",
"    </a>",
"    ]. In the Framingham study, the following reductions in age-adjusted mortality from the time of onset of HF were noted from 1950 through 1969 compared to 1990 through 1999 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The one-year mortality declined from 30 to 28 percent in men and from 28 to 24 percent in women.",
"     </li>",
"     <li>",
"      The five-year mortality declined from 70 to 59 percent in men and from 57 to 45 percent in women; the adjusted reduction in mortality was about 30 percent in both sexes.",
"     </li>",
"     <li>",
"      There was a significant overall trend of a 12 percent reduction in mortality per decade during this time period; almost all of the improvement in mortality occurred after 1980 and particularly after 1990.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A decline in HF mortality was also noted in an analysis from the Mayo Clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/20\">",
"     20",
"    </a>",
"    ]. For the periods 1979 to 1984 compared to 1996 to 2000, the one-year mortality fell from 30 to 21 percent in men and from 20 to 17 percent in women. The five-year mortality fell from 65 to 50 percent in men and from 51 to 46 percent in women. Survival improved most among younger men and least among older women.",
"   </p>",
"   <p>",
"    Lower rates of improvement in HF mortality rates were observed in two later studies of Medicare beneficiaries spanning shorter periods of time [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/18,21\">",
"     18,21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 3,957,520 Medicare beneficiaries hospitalized with HF between 1992 and 1999, the observed one-year mortality rate decreased only slightly (from 32.5 to 31.7 percent) during the study period due to a decline in mortality between 1993 and 1994 [",
"      <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 2,540,838 Medicare beneficiaries hospitalized with HF between 2001 and 2005, the observed one-year mortality rate (37 percent) did not fall over time, although the adjusted hazard of mortality at one-year was slightly lower in 2005 than in 2001 (hazard ratio 0.98; 95% CI, 0.97-0.99) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mortality rates in the placebo arms of clinical drug trials, which represent a selected population, have been variable, depending in large part upon the",
"    <strong>",
"     severity",
"    </strong>",
"    of the HF. In the placebo arms of the angiotensin converting enzyme (ACE) inhibitor trials of patients with systolic dysfunction, in which few patients were taking the two other drugs known to improve survival, beta blockers and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    , the mortality rate was 52 percent at one year for patients with New York Heart Association (NYHA) class III or IV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/22\">",
"     22",
"    </a>",
"    ] compared to 25 percent at two years for NYHA class II to III disease (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]; among patients with asymptomatic left ventricular dysfunction, the incidence of cardiovascular death or symptomatic HF was 39 percent at just over three years (",
"    <a class=\"graphic graphic_figure graphicRef62325 graphicRef70015 graphicRef75136 \" href=\"UTD.htm?20/37/21087\">",
"     figure 1A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The entry criteria and selection biases explain the better outlook in these trials than in the population-based studies. Trial participants generally have fewer complicating illnesses, such as significant ischemic symptoms amenable to therapy or valve disease, fewer older patients, and are more likely to receive optimal therapy. As a result, trials are expected to overestimate survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Predictive models",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of predictors of survival have been identified in patients with HF, such as peak VO2, New York Heart Association (NYHA) functional class, left ventricular ejection fraction, and markers of the adequacy of tissue perfusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=see_link\">",
"     \"Predictors of survival in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although these risk factors correlate with survival on a statistical basis in a large population, their ability to predict survival in individual patients is limited. As a result, a number of retrospective analyses have been used to develop predictive models that utilize multiple indicators to generate a more accurate estimate of prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/26-29\">",
"     26-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential benefits of using prognostic models for HF include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enables patients and families to have a realistic expectation of the prognosis",
"     </li>",
"     <li>",
"      Enables appropriate allocation of resources, including transplantation, mechanical circulatory assist devices, and implantable defibrillators",
"     </li>",
"     <li>",
"      Enables selection of therapies most likely to positively affect the quality and quantity of life",
"     </li>",
"     <li>",
"      Promotes open, honest communication between clinicians, patients, and their families to define the goals of therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Potential hazards of using prognostic models for HF include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The model was derived from a different population of patients",
"     </li>",
"     <li>",
"      Patient compliance, preference, or attitudes are not incorporated",
"     </li>",
"     <li>",
"      New therapies become available, making the models obsolete",
"     </li>",
"     <li>",
"      The patient is not in compensated HF or is not on evidence-based therapies",
"     </li>",
"     <li>",
"      Uncertainty in applying the model to an individual patient cannot be quantified and this uncertainty may be difficult for clinicians to effectively explain to patients and their families",
"     </li>",
"     <li>",
"      Scores from the models replace informed, compassionate, clinician-patient conversations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the limitations of prognostic models, use of a prognostic model should supplement rather than replace the judgment of the clinical team [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/30\">",
"     30",
"    </a>",
"    ]. A study of the predictive accuracy of physicians and HF nurses for estimating risk of hospitalization and death among patients with advanced HF found that nurse estimations of mortality added significantly to the derived prognostic model but physician estimations did not [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/31\">",
"     31",
"    </a>",
"    ]. It was hypothesized that the nurses were better versed in patient psychosocial characteristics that impact HF outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     EFFECT model",
"    </span>",
"    &nbsp;&mdash;&nbsp;The EFFECT model was derived, tested, and intended to be used in patients hospitalized for HF [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/26\">",
"     26",
"    </a>",
"    ]. The derivation cohort included 2624 patients in the EFFECT study, who presented with HF at 34 hospitals in Ontario, Canada between 1999 and 2001. The model was then validated in 1407 patients presenting between 1997 and 1999.",
"   </p>",
"   <p>",
"    Multiple clinical characteristics, including both HF-related factors (respiratory rate, systolic pressure, blood urea nitrogen, and serum sodium concentration) and comorbidities (eg, COPD, anemia, malignancy) were correlated with 30-day and one-year mortality. Points were assigned to each significant predictor; the sum of the points results in a risk score ranging from &le;60 (very low; 30-day mortality &lt;1 percent and one year mortality &lt;10 percent) to &gt;150 (very high; 30-day mortality &gt;50 percent and one year mortality &gt;70 percent).",
"   </p>",
"   <p>",
"    An on-line calculator for this risk model is available at",
"    <a class=\"external\" href=\"file://www.ccort.ca/CHFriskmodel.aspx\">",
"     www.ccort.ca/CHFriskmodel.aspx",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Heart Failure Survival Score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Heart Failure Survival Score (HFSS) is another prospectively validated model, developed in and for patients with advanced HF (NYHA class III or IV) (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/27\">",
"     27",
"    </a>",
"    ]. This score was derived from a multivariable analysis of 268 ambulatory patients referred for consideration of cardiac transplantation and validated in 199 similar patients. The predictors of survival in the HFSS include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence or absence of coronary artery disease",
"     </li>",
"     <li>",
"      Resting heart rate",
"     </li>",
"     <li>",
"      LVEF",
"     </li>",
"     <li>",
"      Mean arterial blood pressure",
"     </li>",
"     <li>",
"      Presence or absence of an intraventricular conduction delay on ECG",
"     </li>",
"     <li>",
"      Serum sodium",
"     </li>",
"     <li>",
"      Peak VO2",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In an invasive version of the HFSS, pulmonary capillary wedge pressure is included as an eighth variable. The HFSS stratifies patients into low, medium, and high risk categories, based upon a sum of the variables above multiplied by defined coefficients. Among the patients in the validation sample, one-year survival rates without transplant for these three strata were 88, 60, and 35 percent, respectively.",
"   </p>",
"   <p>",
"    The HFSS is often used as an aid to selecting patients for cardiac transplantation. However, the above survival rates may not be applicable to current practice since the model was derived before the use of modern therapies that improve survival in patients with HF, including beta blockers, angiotensin II receptor blockers, aldosterone antagonists, implantable cardioverter-defibrillators, and cardiac resynchronization therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/32\">",
"     32",
"    </a>",
"    ]. In addition, some of these therapies directly affect some of the parameters in the risk model (eg, beta blockers and resting heart rate, and cardiac resynchronization therapy and conduction delay). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=see_link&amp;anchor=H11#H11\">",
"     \"Indications and contraindications for cardiac transplantation\", section on 'Heart Failure Survival Score'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Seattle Heart Failure Model",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Seattle Heart Failure Model differs from the prior models in two ways [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The model was derived and validated in a broad HF population, including both general outpatients and advanced HF patients.",
"     </li>",
"     <li>",
"      The model incorporates a wide range of readily available clinical variables, including medications and devices.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The model was derived in 1125 advanced HF patients from the PRAISE trial (average LVEF 21 percent, average NYHA class 3.6). None of the patients in the derivation cohorts were treated with beta blockers, aldosterone antagonists, or ICDs, but validation of the model in cohorts from subsequent trials evaluated the impact of these interventions. The model was prospectively validated in five additional cohorts totaling 9942 HF patients and 17,307 person-years of follow-up.",
"   </p>",
"   <p>",
"    The diversity of the validation cohorts is illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Average LVEF ranged from 22 to 35 percent.",
"     </li>",
"     <li>",
"      Average NYHA class ranged from 2.2 to 2.9 (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Wide ranges of use of beta blockers (24 to 72 percent) and potassium-sparing diuretics (5 to 35 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Across these populations, the model provided an extremely accurate estimate of one-, two-, and three-year survival (R values ranging from 0.97 to 0.99).",
"   </p>",
"   <p>",
"    The Seattle model also provides information about the likely mode of death. In an analysis of 10,538 ambulatory patients with predominantly systolic HF (NYHA class II to IV), the score was predictive of the risk of sudden death and of pump failure [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/33\">",
"     33",
"    </a>",
"    ]. Compared with patients with a score of 0, the risk of sudden death progressively increased with higher scores, up to a sevenfold higher risk with a score of 4. Conversely, the proportion of deaths caused by sudden death versus pump failure decreased from a ratio of 7:1 with a score of 0 to a ratio of 1:2 with a score of 4.",
"   </p>",
"   <p>",
"    An online calculator is available at",
"    <a class=\"external\" href=\"file://www.seattleheartfailuremodel.org/\">",
"     www.SeattleHeartFailureModel.org",
"    </a>",
"    . The calculator can also estimate the effect of adding new therapies on the risk of mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Effect of demographic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The survival of patients with HF is influenced by age, gender, race and the cause of the cardiomyopathy. However, many of these studies included patients with both systolic dysfunction and patients with preserved ejection fraction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Effect of age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mortality rate in treated patients with HF increases with age [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/10,34-36\">",
"     10,34-36",
"    </a>",
"    ]. In a report from the Framingham Study, for example, mortality increased with advancing age (hazard ratio 1.27 and 1.61 per decade in men and women, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/10\">",
"     10",
"    </a>",
"    ]. Similar findings were noted in the population-based study from Canada [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/34\">",
"     34",
"    </a>",
"    ]. Patients aged 65 to 74 and &ge;75 had an independent increase in one year mortality compared to patients aged 25 to 49 (odds ratio 2.18 and 4.24, respectively).",
"   </p>",
"   <p>",
"    The prognosis of HF in elderly adults was assessed in a community-based review of over 5500 persons from the Cardiovascular Health Study [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/37\">",
"     37",
"    </a>",
"    ]. Among the 5 percent with HF, the LVEF was normal in 63 percent, borderline low in 15 percent, and overtly reduced in 22 percent. Compared to the mortality rate of 25 deaths per 1000 person-years in those without HF or left ventricular dysfunction, the mortality rates were 87, 115, and 154 per 1000 person-years in those with normal, borderline, and reduced left ventricular function, respectively.",
"   </p>",
"   <p>",
"    Despite the increase in risk in the elderly, mortality improvements have occurred over time [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/19,38\">",
"     19,38",
"    </a>",
"    ]. In the report from the Framingham Heart Study mentioned above of subjects between the ages of 65 and 74, five year mortality between 1950-69 and 1990-99 fell from 66 to 54 percent in men and 47 to 40 percent in women who survived at least 30 days after the onset of HF [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Effect of gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis has generally been better in women than men with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/10,19,39\">",
"     10,19,39",
"    </a>",
"    ]. In data from the Framingham Heart Study, the median survival time after diagnosis was 3.2 years in women and 1.7 years in men; after five years, 38 percent of women and 25 percent of men were alive [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/10\">",
"     10",
"    </a>",
"    ]. If only persons who survived the first 90 days were considered, thereby excluding patients with acute myocardial infarction and those requiring early surgery, the five year survival statistics improved to 53 percent in women and 35 percent in men. In the period from 1990 to 1999, five year survival was 60 percent in women compared to 46 percent in men [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A reduced risk in women has also been noted in modern therapeutic trials [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/39-43\">",
"     39-43",
"    </a>",
"    ]. A pooled analysis of five randomized trials testing a variety of therapies among patients with reduced LVEF (PRAISE, PRAISE II, MERIT HF, VEST, and PROMISE) included a total of 8791 men and 2851 women [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/39\">",
"     39",
"    </a>",
"    ]. In multivariable analysis, female gender was associated with significantly longer survival (hazard ratio 0.77).",
"   </p>",
"   <p>",
"    Similar findings were noted in a comparison of outcomes in 2400 women and 5199 men in the CHARM trial, which included patients with both reduced and preserved LVEF [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/43\">",
"     43",
"    </a>",
"    ]. Women had lower risks of most fatal and nonfatal outcomes; these differences were not explained by LVEF or the cause of heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Effect of race",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of race on the prognosis of HF is uncertain since different studies have revealed contrasting findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher mortality in blacks in a post hoc analysis from the SOLVD trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      in patients with asymptomatic LV dysfunction or overt HF [",
"      <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=see_link&amp;anchor=H8#H8\">",
"       \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\", section on 'Influence of race'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lower mortality in blacks in an analysis of nearly 30,000 Medicare beneficiaries hospitalized for HF in 1998 and 1999 [",
"      <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      No difference in mortality between whites and blacks in a post hoc analysis from the DIG trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Effect of cause of cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of HF may be predictive of long-term outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=see_link\">",
"     \"Definition and classification of the cardiomyopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This was addressed by one study of 1230 patients with an initially unexplained cardiomyopathy, which analyzed the outcome based upon the etiology of the cardiomyopathy; after a mean follow-up of 4.4 years, 34 percent of patients died and 4.6 percent underwent cardiac transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/48\">",
"     48",
"    </a>",
"    ]. Compared to those with an idiopathic cardiomyopathy, which served as the reference group, the following findings were noted (",
"    <a class=\"graphic graphic_figure graphicRef75646 \" href=\"UTD.htm?24/48/25358\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Survival was better in patients with peripartum cardiomyopathy (hazard ratio 0.31).",
"     </li>",
"     <li>",
"      Survival was worse in patients with infiltrative myocardial disease, particularly amyloidosis or hemochromatosis (hazard ratio 7.41 and 8.88, respectively), HIV infection (hazard ratio 5.86),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      therapy (hazard ratio 3.46), ischemic heart disease (hazard ratio 1.52), or connective tissue disease (hazard ratio 1.75).",
"     </li>",
"     <li>",
"      Survival was the same in patients with hypertension, myocarditis, sarcoidosis, substance abuse, or other causes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a review of patients from the SOLVD treatment trials, the presence of diabetes had a differential impact on mortality in patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/49\">",
"     49",
"    </a>",
"    ]. In adjusted analyses, diabetes significantly increased all-cause mortality in patients with ischemic cardiomyopathy but not those with nonischemic cardiomyopathy (relative risk 1.37 and 0.98, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Natural history of recent onset IDC",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of recent onset idiopathic dilated cardiomyopathy (IDC) and HF is variable and difficult to predict. Although the one year mortality may be as high as 25 percent, a substantial proportion of these patients improve spontaneously over time.",
"   </p>",
"   <p>",
"    The frequency of reversible dysfunction was illustrated by the IMAC-2 study of 373 patients with recent onset IDC or myocarditis with LVEF &lt;40 percent (mean 24 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/50\">",
"     50",
"    </a>",
"    ]. At six months, 70 percent demonstrated an increase in LVEF by at least 10 units and 30 percent had an increase of at least 20 units. Forty percent had an LVEF of &ge;45 and 25 percent had an LVEF &ge;50 percent at six months. Transplantation-free survival at one, two, and four years was 94, 92, and 88 percent.",
"   </p>",
"   <p>",
"    The myocardial contractile response to exogenous catecholamines may be a method to predict those patients who will recover. This hypothesis was tested in a series of 22 patients with recently diagnosed (4&plusmn;3 months) IDC and a LVEF &lt;40 percent who underwent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography; the change in LVEF and left ventricular geometry (sphericity index) in response to dobutamine predicted recovery of left ventricular function [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/51\">",
"     51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with an LVEF &gt;40 percent at six months had an increase of &gt;14 percentage points in baseline LVEF with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      while the improvement was &lt;6 percentage points in those patients with an LVEF that remained &lt;40 percent during follow-up.",
"     </li>",
"     <li>",
"      The left ventricular sphericity index in end-diastole on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      , defined as the ratio of left ventricular length (from the apex to the middle of the mitral annular plane) to left ventricular width (at the midpoint of left ventricular length in the four chamber view), correlated with the sphericity index at six months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Seasonal variation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have found a seasonal pattern of deaths from myocardial infarction and sudden death, with more fatal events occurring in the winter than the summer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16250?source=see_link\">",
"     \"Psychosocial and other social factors in acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/15/23800?source=see_link\">",
"     \"Psychosocial factors in sudden cardiac arrest\"",
"    </a>",
"    .) A similar seasonal variation has been seen in men and women with chronic HF [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. In a large study from France, deaths from HF peaked during the winter months of December and January [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/52\">",
"     52",
"    </a>",
"    ]. The distribution of monthly deaths differed by up to 35 percent when January was compared to August, which is when deaths were the lowest. Hospitalizations for HF followed the same seasonal pattern, with a winter-spring predominance (",
"    <a class=\"graphic graphic_figure graphicRef61776 \" href=\"UTD.htm?40/62/41965\">",
"     figure 3",
"    </a>",
"    ). Approximately one-fifth of the excess in winter admissions has been attributed to respiratory disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Circadian rhythm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden death in patients with HF does not follow a circadian rhythm, in contrast to the circadian variation (most deaths between 6 AM and 12 PM) seen in the occurrence of out-of-hospital sudden death or acute myocardial infarction in the general population. An analysis of 1153 patients in the PRAISE trial found a uniform distribution of sudden death in patients with a nonischemic cardiomyopathy, while there was a PM peak in those with an ischemic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/54\">",
"     54",
"    </a>",
"    ]. This PM peak was not altered by the use of antiischemic or antithrombotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/15/23800?source=see_link\">",
"     \"Psychosocial factors in sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Diastolic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of patients with symptomatic HF with normal LV systolic function is less well defined than in those with systolic dysfunction. Studies comparing survival rates with systolic and diastolic HF have provided mixed results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment and prognosis of diastolic heart failure\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10444215\">",
"    <span class=\"h1\">",
"     EFFECT OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized controlled trials have demonstrated that certain drugs, devices, and other care strategies improve survival rates and reduce risk of hospitalization in patients with heart failure. Although these trials provide strong evidence of benefit, trial participants are often younger and have fewer comorbidities than clinical patient populations and the conduct of care in trials differs from that in routine clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/55\">",
"     55",
"    </a>",
"    ]. Therefore, observational studies of process-of-care measures (including adherence to evidence-based therapies) have been performed to assess the effects on outcome in real world settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10444624\">",
"    <span class=\"h2\">",
"     Evidence from clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence from randomized trials has demonstrated the efficacy of certain drugs and devices in the treatment of systolic heart failure as discussed in detail in the various topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10823?source=see_link\">",
"     \"Rationale for and mechanisms of benefit of cardiac resynchronization therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although improved, mortality is still appreciable with appropriate medical therapy. For example, the following results were noted in the treatment arms of the major ACE inhibitor trials (",
"    <a class=\"graphic graphic_figure graphicRef62325 graphicRef70015 graphicRef75136 \" href=\"UTD.htm?20/37/21087\">",
"     figure 1A-C",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mortality rate was 36 percent at one year for patients with NYHA class III or IV disease compared to 52 percent in those not receiving an ACE inhibitor [",
"      <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/22\">",
"       22",
"      </a>",
"      ]. Similar results were noted in another study of 499 patients with class III or IV HF, 75 percent of whom were receiving an ACE inhibitor and 50 percent of whom were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/56\">",
"       56",
"      </a>",
"      ]. The one-year mortality was 35 percent and the rate of death or hospital readmission (2.05 times and 27.6 days per year) was 81 percent.",
"     </li>",
"     <li>",
"      The mortality rate was 18 to 20 percent at two years for NYHA class II to III disease compared to 25 percent in those not receiving an ACE inhibitor [",
"      <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among patients with asymptomatic left ventricular dysfunction, the incidence of cardiovascular death or symptomatic HF was 30 percent at just over three years compared to 39 percent in those not receiving an ACE inhibitor [",
"      <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further improvements have been made with the addition of beta blockers and aldosterone antagonist (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    ) to ACE inhibition (",
"    <a class=\"graphic graphic_figure graphicRef78949 graphicRef76232 \" href=\"UTD.htm?4/47/4863\">",
"     figure 4A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=see_link\">",
"     \"Use of aldosterone antagonists in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The survival benefit associated with ACE inhibitors and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    plus nitrates, although statistically significant, is relatively modest in absolute terms. Most studies have reported a 15 to 20 percent reduction in overall mortality. In the SOLVD trial of New York Heart Association Class II and III HF, for example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    lowered the four-year mortality rate from 42 to 36 percent; this represents an absolute improvement of 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/23\">",
"     23",
"    </a>",
"    ]. Averaging the benefit from these studies through the entire treated population translates into a mean increase in survival of",
"    <strong>",
"     less than six months",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/11\">",
"     11",
"    </a>",
"    ]. Thus, the benefit is apparent only in large populations.",
"   </p>",
"   <p>",
"    The survival benefit may be somewhat greater with beta blockers. As an example, a meta-analysis of 21 trials involving 5849 patients treated for a median of six months found that beta blockers reduced overall mortality by 39 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/57\">",
"     57",
"    </a>",
"    ]. It was estimated that during the first year this therapy would save 3.8 lives per 100 patients treated [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/58\">",
"     58",
"    </a>",
"    ]. In the MERIT-HF trial of almost 4000 patients with NYHA class II to IV HF who were treated with ACE inhibitors and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    produced a significant reduction in one-year mortality (7.2 versus 11 percent with placebo) (",
"    <a class=\"graphic graphic_figure graphicRef78949 \" href=\"UTD.htm?38/42/39597\">",
"     figure 4A",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The magnitude of benefit can be illustrated by the marked short-term improvement in survival of patients with NYHA class IV HF. In controlled trials, one-year mortality fell from 52 percent in the CONSENSUS trial published in 1987 in which ACE inhibitors and beta blockers were not used [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/22\">",
"     22",
"    </a>",
"    ] to 11.4 percent in the COPERNICUS trial published in 2001 in which both drugs were used [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/60\">",
"     60",
"    </a>",
"    ]. Although it is not possible to compare these trials directly due to differences in entry criteria, the mortality rate in some groups of patients with advanced HF is now in the range of 15 to 25 percent. The observed improvement is due to the use of HF drugs (ACE inhibitors, beta blockers) and other modalities aimed at underlying diseases (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , statins).",
"   </p>",
"   <p>",
"    In addition to these specific therapies for HF, better control of hypertension and of coronary risk factors also contribute to the improvement in outcome.",
"   </p>",
"   <p>",
"    Unfortunately, there are major lags in the appropriate adoption of the drugs that improve survival in HF [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/11,61,62\">",
"     11,61,62",
"    </a>",
"    ]. Even among treated patients, the doses used are often lower than those in the clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\", section on 'ACE inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10444222\">",
"    <span class=\"h2\">",
"     Process-of-care measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies of inpatient process-of-care measures (including adherence to evidence-based therapies) have found that some are associated with post-discharge outcomes. The following are examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The impact of adherence to Joint Commission on Accreditation of Healthcare Organizations (JCAHO) HF core measures was evaluated in a study of 2958 patients in a 20-hospital system. A positive and incremental relationship between degree of adherence and one-year survival was demonstrated [",
"      <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study of data for 20,441 Medicare beneficiaries in OPTIMIZE-HF found that several hospital-level process measures (including various evidence-based drug and device therapies) were associated with reduced one-year survival [",
"      <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      On the other hand, a study of 22,750 Medicare fee-for-service beneficiaries found that a composite score of hospital-level process measures was not associated with one-year survival or readmission. However, a component of the score (prescription of beta-blockers at discharge) was independently associated with lower mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similarly, some outpatient process-of-care measures are associated with improved outcomes, as illustrated by an observational study of 15,177 patients with left ventricular ejection fraction &le;35 percent and chronic heart failure or post-myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/66\">",
"     66",
"    </a>",
"    ]. Two-year survival was associated with process measures including adherence to various evidence-based drug and device therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     CAUSES OF DEATH IN HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two main causes of death in patients with HF are sudden or arrhythmic death (defined as death within one hour of the onset of cardiovascular collapse in a previously stable patient) and progressive pump failure (defined as cardiac death with preceding symptomatic or hemodynamic deterioration) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In a 38 year follow-up of patients in the Framingham Heart Study, the presence of HF significantly increased overall and sudden cardiac death (SCD) mortality by five-fold (",
"    <a class=\"graphic graphic_figure graphicRef58658 \" href=\"UTD.htm?31/17/32029\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/67\">",
"     67",
"    </a>",
"    ]. The SCD death potential in men and women with HF was as great as that noted in patients with overt coronary heart disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     SCD and progressive HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Published series suggest a relatively consistent pattern with 30 to 50 percent of all cardiac deaths in patients with HF being categorized as sudden deaths, with or without preceding symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/15,23,25,59,67,68\">",
"     15,23,25,59,67,68",
"    </a>",
"    ]. However, it is often difficult to distinguish those dying suddenly and unexpectedly from those experiencing terminal arrhythmias in the setting of progressive hemodynamic deterioration [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/69-71\">",
"     69-71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result, clinical studies have classified deaths in differing ways. In the AIRE trial, 45 percent of patients who died suddenly had severe or worsening HF prior to their death; only 39 percent of sudden deaths were thought to be due to arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/70\">",
"     70",
"    </a>",
"    ]. In the control arm of the MADIT II trial, of 72 deaths considered to be cardiac, 31 percent occurred within one hour of symptom onset, 36 percent occurred greater than one hour after symptom onset, and 33 percent were unwitnessed [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/71\">",
"     71",
"    </a>",
"    ]. In the ICD arm, defibrillator therapy reduced the incidence of deaths occurring within one hour of symptoms and unwitnessed deaths, suggesting that these groups included most of the patients with terminal arrhythmia.",
"   </p>",
"   <p>",
"    It has been suggested that progressive pump failure, sudden death, and sudden death during episodes of clinical worsening each account for approximately one-third of deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/69\">",
"     69",
"    </a>",
"    ]. Ventricular tachycardia degenerating into ventricular fibrillation is the most common cause of sudden death; a bradyarrhythmia or pulseless electrical activity (electromechanical dissociation) is responsible in 5 to 33 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/69\">",
"     69",
"    </a>",
"    ], although the frequency may be increased in patients with advanced HF [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The three major classes of drugs that improve survival in HF - angiotensin converting enzyme (ACE) inhibitors, beta blockers, and aldosterone antagonists - have different effects on the causes of death. The benefit of ACE inhibitors is primarily derived from prevention of progressive myocardial dysfunction, rather than prevention of SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/22,23,25,68\">",
"     22,23,25,68",
"    </a>",
"    ]. Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    significantly reduced sudden death by 30 percent in the AIRE trial, most of these deaths as mentioned above were due to severe or worsening HF rather than arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/70\">",
"     70",
"    </a>",
"    ]. In contrast, beta blockers and, in patients with class IV HF,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    reduce both SCD and death from progressive HF [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/57,59,73\">",
"     57,59,73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/55/3962?source=see_link\">",
"     \"Use of diuretics in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prognostic significance of ICD shocks in patients with HF is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link&amp;anchor=H21#H21\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Prognostic significance of ICD shocks'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Role of ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although sudden death is most often the result of a ventricular tachyarrhythmia, the role of an acute coronary event in these patients may be underestimated. The prevalence of an acute coronary finding (coronary thrombus, ruptured plaque, or myocardial infarction) and its relationship to sudden death was examined in an autopsy study of 171 patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?3/61/4058/abstract/74\">",
"     74",
"    </a>",
"    ]. In patients with significant coronary artery disease, an acute coronary finding was found in 54 percent who died suddenly and in 32 percent who died of myocardial failure, although an acute coronary event had not been clinically diagnosed before death. In contrast, an acute coronary finding was uncommon in those without coronary disease, present in only 5 percent of those dying from sudden death and 10 percent of those dying from myocardial failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=see_link\">",
"       \"Patient information: Heart failure (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10440925\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hospitalization for heart failure is a marker for poor prognosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Hospitalization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term mortality rates for patients with HF have improved over time, although later studies indicate a slower rate of improvement. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Long-term mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Predictive models such as the EFFECT model, the Heart Failure Survival Score, and the Seattle Heart Failure Model should supplement rather than replace the judgment of the clinical team. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Predictive models'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The survival of patients with heart failure worsens with age, is generally better in women than men, and varies among different causes of cardiomyopathy. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Effect of demographic factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Survival with heart failure is most limited in patients with amyloidosis, hemochromatosis, HIV infection, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      toxicity. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Effect of cause of cardiomyopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evidence from randomized trials has demonstrated the efficacy of certain drugs and devices in the treatment of systolic heart failure as discussed in detail in the various topic reviews. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"       \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link\">",
"       \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10823?source=see_link\">",
"       \"Rationale for and mechanisms of benefit of cardiac resynchronization therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Observational studies of inpatient process-of-care measures (including adherence to evidence-based therapies) have found that some are associated with post-discharge outcomes. (See",
"      <a class=\"local\" href=\"#H10444222\">",
"       'Process-of-care measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The two main causes of death in patients with HF are sudden or arrhythmic death and progressive pump failure. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Causes of death in HF'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/1\">",
"      Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22:6A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/2\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/3\">",
"      Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007; 116:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/4\">",
"      Michalsen A, K&ouml;nig G, Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart 1998; 80:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/5\">",
"      Opasich C, Rapezzi C, Lucci D, et al. Precipitating factors and decision-making processes of short-term worsening heart failure despite \"optimal\" treatment (from the IN-CHF Registry). Am J Cardiol 2001; 88:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/6\">",
"      Tsuyuki RT, McKelvie RS, Arnold JM, et al. Acute precipitants of congestive heart failure exacerbations. Arch Intern Med 2001; 161:2337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/7\">",
"      Lee DS, Austin PC, Stukel TA, et al. \"Dose-dependent\" impact of recurrent cardiac events on mortality in patients with heart failure. Am J Med 2009; 122:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/8\">",
"      Krumholz HM, Parent EM, Tu N, et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med 1997; 157:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/9\">",
"      Cowie MR, Wood DA, Coats AJ, et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart 2000; 83:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/10\">",
"      Ho KK, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/11\">",
"      Rodeheffer RJ, Jacobsen SJ, Gersh BJ, et al. The incidence and prevalence of congestive heart failure in Rochester, Minnesota. Mayo Clin Proc 1993; 68:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/12\">",
"      Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999; 33:1948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/13\">",
"      Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992; 20:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/14\">",
"      MacIntyre K, Capewell S, Stewart S, et al. Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation 2000; 102:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/15\">",
"      Mosterd A, Cost B, Hoes AW, et al. The prognosis of heart failure in the general population: The Rotterdam Study. Eur Heart J 2001; 22:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/16\">",
"      Polanczyk CA, Rohde LE, Dec GW, DiSalvo T. Ten-year trends in hospital care for congestive heart failure: improved outcomes and increased use of resources. Arch Intern Med 2000; 160:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/17\">",
"      Baker DW, Einstadter D, Thomas C, Cebul RD. Mortality trends for 23,505 Medicare patients hospitalized with heart failure in Northeast Ohio, 1991 to 1997. Am Heart J 2003; 146:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/18\">",
"      Curtis LH, Greiner MA, Hammill BG, et al. Early and long-term outcomes of heart failure in elderly persons, 2001-2005. Arch Intern Med 2008; 168:2481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/19\">",
"      Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/20\">",
"      Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA 2004; 292:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/21\">",
"      Kosiborod M, Lichtman JH, Heidenreich PA, et al. National trends in outcomes among elderly patients with heart failure. Am J Med 2006; 119:616.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/22\">",
"      Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987; 316:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/23\">",
"      Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/24\">",
"      Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/25\">",
"      Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 1992; 327:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/26\">",
"      Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003; 290:2581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/27\">",
"      Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997; 95:2660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/28\">",
"      Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006; 113:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/29\">",
"      Brophy JM, Dagenais GR, McSherry F, et al. A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction. Am J Med 2004; 116:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/30\">",
"      Goldberg LR, Jessup M. A time to be born and a time to die. Circulation 2007; 116:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/31\">",
"      Yamokoski LM, Hasselblad V, Moser DK, et al. Prediction of rehospitalization and death in severe heart failure by physicians and nurses of the ESCAPE trial. J Card Fail 2007; 13:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/32\">",
"      Gardner RS, McDonagh TA, MacDonald M, et al. Who needs a heart transplant? Eur Heart J 2006; 27:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/33\">",
"      Mozaffarian D, Anker SD, Anand I, et al. Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation 2007; 116:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/34\">",
"      Jong P, Vowinckel E, Liu PP, et al. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med 2002; 162:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/35\">",
"      Pulignano G, Del Sindaco D, Tavazzi L, et al. Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry). Am Heart J 2002; 143:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/36\">",
"      White HD, Aylward PE, Huang Z, et al. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation 2005; 112:3391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/37\">",
"      Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med 2002; 137:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/38\">",
"      Barker WH, Mullooly JP, Getchell W. Changing incidence and survival for heart failure in a well-defined older population, 1970-1974 and 1990-1994. Circulation 2006; 113:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/39\">",
"      Frazier CG, Alexander KP, Newby LK, et al. Associations of gender and etiology with outcomes in heart failure with systolic dysfunction: a pooled analysis of 5 randomized control trials. J Am Coll Cardiol 2007; 49:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/40\">",
"      Simon T, Mary-Krause M, Funck-Brentano C, Jaillon P. Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation 2001; 103:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/41\">",
"      Adams KF Jr, Sueta CA, Gheorghiade M, et al. Gender differences in survival in advanced heart failure. Insights from the FIRST study. Circulation 1999; 99:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/42\">",
"      Ghali JK, Pi&ntilde;a IL, Gottlieb SS, et al. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation 2002; 105:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/43\">",
"      O'Meara E, Clayton T, McEntegart MB, et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2007; 115:3111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/44\">",
"      Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001; 344:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/45\">",
"      Dries DL, Strong MH, Cooper RS, Drazner MH. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol 2002; 40:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/46\">",
"      Rathore SS, Foody JM, Wang Y, et al. Race, quality of care, and outcomes of elderly patients hospitalized with heart failure. JAMA 2003; 289:2517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/47\">",
"      Mathew J, Wittes J, McSherry F, et al. Racial differences in outcome and treatment effect in congestive heart failure. Am Heart J 2005; 150:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/48\">",
"      Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/49\">",
"      Dries DL, Sweitzer NK, Drazner MH, et al. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol 2001; 38:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/50\">",
"      McNamara DM, Starling RC, Cooper LT, et al. Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study. J Am Coll Cardiol 2011; 58:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/51\">",
"      Naqvi TZ, Goel RK, Forrester JS, Siegel RJ. Myocardial contractile reserve on dobutamine echocardiography predicts late spontaneous improvement in cardiac function in patients with recent onset idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1999; 34:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/52\">",
"      Boulay F, Berthier F, Sisteron O, et al. Seasonal variation in chronic heart failure hospitalizations and mortality in France. Circulation 1999; 100:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/53\">",
"      Stewart S, McIntyre K, Capewell S, McMurray JJ. Heart failure in a cold climate. Seasonal variation in heart failure-related morbidity and mortality. J Am Coll Cardiol 2002; 39:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/54\">",
"      Carson PA, O'Connor CM, Miller AB, et al. Circadian rhythm and sudden death in heart failure: results from Prospective Randomized Amlodipine Survival Trial. J Am Coll Cardiol 2000; 36:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/55\">",
"      Allen LA. Observational process-outcome associations for real-world ambulatory heart failure care: moving toward clarity, or clouding the view? Circulation 2011; 123:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/56\">",
"      Zannad F, Briancon S, Juilliere Y, et al. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study. Epid&eacute;miologie de l'Insuffisance Cardiaque Avanc&eacute;e en Lorraine. J Am Coll Cardiol 1999; 33:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/57\">",
"      Bonet S, Agust&iacute; A, Arnau JM, et al. Beta-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients' characteristics: a meta-analysis of clinical trials. Arch Intern Med 2000; 160:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/58\">",
"      Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 2001; 134:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/59\">",
"      Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/60\">",
"      Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/61\">",
"      Stafford RS, Saglam D, Blumenthal D. National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure. Arch Intern Med 1997; 157:2460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/62\">",
"      Luzier AB, Forrest A, Adelman M, et al. Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure. Am J Cardiol 1998; 82:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/63\">",
"      Kfoury AG, French TK, Horne BD, et al. Incremental survival benefit with adherence to standardized heart failure core measures: a performance evaluation study of 2958 patients. J Card Fail 2008; 14:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/64\">",
"      Hernandez AF, Hammill BG, Peterson ED, et al. Relationships between emerging measures of heart failure processes of care and clinical outcomes. Am Heart J 2010; 159:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/65\">",
"      Patterson ME, Hernandez AF, Hammill BG, et al. Process of care performance measures and long-term outcomes in patients hospitalized with heart failure. Med Care 2010; 48:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/66\">",
"      Fonarow GC, Albert NM, Curtis AB, et al. Associations between outpatient heart failure process-of-care measures and mortality. Circulation 2011; 123:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/67\">",
"      Kannel WB, Wilson PW, D'Agostino RB, Cobb J. Sudden coronary death in women. Am Heart J 1998; 136:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/68\">",
"      Pfeffer MA, Braunwald E, Moy&eacute; LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/69\">",
"      Narang R, Cleland JG, Erhardt L, et al. Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur Heart J 1996; 17:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/70\">",
"      Cleland JG, Erhardt L, Murray G, et al. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur Heart J 1997; 18:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/71\">",
"      Greenberg H, Case RB, Moss AJ, et al. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol 2004; 43:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/72\">",
"      Luu M, Stevenson WG, Stevenson LW, et al. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation 1989; 80:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/73\">",
"      Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/61/4058/abstract/74\">",
"      Uretsky BF, Thygesen K, Armstrong PW, et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 2000; 102:611.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3501 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-71122602D8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_61_4058=[""].join("\n");
var outline_f3_61_4058=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10440925\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STAGES OF HF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HOSPITALIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SURVIVAL IN HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      In-hospital mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Long-term mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Predictive models",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - EFFECT model",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Heart Failure Survival Score",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Seattle Heart Failure Model",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Effect of demographic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Effect of age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Effect of gender",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Effect of race",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Effect of cause of cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Natural history of recent onset IDC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Seasonal variation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Circadian rhythm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Diastolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10444215\">",
"      EFFECT OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10444624\">",
"      Evidence from clinical trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10444222\">",
"      Process-of-care measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      CAUSES OF DEATH IN HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SCD and progressive HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Role of ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10440925\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3501\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3501|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?1/38/1637\" title=\"algorithm 1\">",
"      Stages evolution HF and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3501|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/61/23517\" title=\"figure 1A\">",
"      ACE inhibitor advanced HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/28/10701\" title=\"figure 1B\">",
"      ACE inhibitor moderate HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/15/11517\" title=\"figure 1C\">",
"      ACE inhibitor in LV dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/48/25358\" title=\"figure 2\">",
"      Etiology cardiomyopathy outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/62/41965\" title=\"figure 3\">",
"      Seasonal variation death HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/42/39597\" title=\"figure 4A\">",
"      Mortality metoprolol HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/14/31981\" title=\"figure 4B\">",
"      Spironolactone in heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/17/32029\" title=\"figure 5\">",
"      Heart failure predicts sudden cardiac death and mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3501|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=related_link\">",
"      Definition and classification of the cardiomyopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15497?source=related_link\">",
"      Epidemiology and causes of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28601?source=related_link\">",
"      Evaluation and management of asymptomatic left ventricular systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=related_link\">",
"      Indications and contraindications for cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=related_link\">",
"      Predictors of survival in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16250?source=related_link\">",
"      Psychosocial and other social factors in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/15/23800?source=related_link\">",
"      Psychosocial factors in sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10823?source=related_link\">",
"      Rationale for and mechanisms of benefit of cardiac resynchronization therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=related_link\">",
"      Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37929?source=related_link\">",
"      Strategies to reduce hospitalizations in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=related_link\">",
"      Use of aldosterone antagonists in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/55/3962?source=related_link\">",
"      Use of diuretics in patients with heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_61_4059="Immunodeficiency cancer risk";
var content_f3_61_4059=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Immune deficiency diseases predisposing to neoplastic disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        X-linked lymphoproliferative disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bruton agammaglobulinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe combined immunodeficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wiskott-Aldrich syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgA deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Common variable immunodeficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DiGeorge syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ataxia-telangiectasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chediak-Higashi syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_61_4059=[""].join("\n");
var outline_f3_61_4059=null;
var title_f3_61_4060="Home playground safety";
var content_f3_61_4060=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Consumer product safety commission recommendations for home playground safety",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       A shock-absorbing surface should be installed around the play equipment and regularly maintained:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       If wood chips, mulch, or shredded rubber is used, a depth of at least 9 inches should be maintained for play equipment up to 7 feet high",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       If sand or pea gravel is used, a depth of at least 9 inches should be maintained for play equipment up to 5 feet high",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Alternatively, surfacing mats made of",
"       <strong>",
"        safety-tested",
"       </strong>",
"       rubber or rubber-like material can be used",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Install protective surfacing at least 6 feet in all directions from play equipment. For swings, be sure surfacing extends in back and front, twice the height of the suspending bar.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Never",
"       </strong>",
"       attach--or allow children to attach--ropes, jump ropes, clotheslines, or pet leashes to play equipment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Check for hazardous hardware (eg, open \"S\" hooks or protruding bolt ends)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Check for openings in guardrails or between ladder rungs that could trap children; these spaces should measure less than 3.5 inches or more than 9 inches",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Make sure platforms and ramps have guardrails to prevent falls",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Check for sharp points or edges in equipment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Remove tripping hazards, like exposed concrete footings, tree stumps, and rocks",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Regularly check play equipment and surfacing to make sure both are in good condition",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Carefully supervise children on play equipment to make sure they are safe",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Consumer Product Safety Commission. Home Playground Equipment-Related Deaths and Injuries. CPSC Document available at file://www.cpsc.gov/playgrnd.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_61_4060=[""].join("\n");
var outline_f3_61_4060=null;
var title_f3_61_4061="Clinical features SD";
var content_f3_61_4061=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F52735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F52735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The clinical diagnostic features of semantic aphasia and associative agnosia (SD): Clinical profile",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Semantic disorder (impaired understanding of word meaning and/or object identity) is the dominant feature initially and throughout the disease course. Other aspects of cognition, including autobiographic memory, are intact or relatively well preserved.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       I. Core diagnostic features",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       A. Insidious onset and gradual progression",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       B. Language disorder characterized by",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       1. Progressive, fluent, empty spontaneous speech",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       2. Loss of word meaning, manifest by impaired naming",
"       <em>",
"        and",
"       </em>",
"       comprehension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       3. Semantic paraphasias",
"       <em>",
"        and/or",
"       </em>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       C. Perceptual disorder characterized by",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       1. Prosopagnosia: impaired recognition of identity of familiar faces",
"       <em>",
"        and/or",
"       </em>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       2. Associative agnosia: impaired recognition of object identity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       D. Preserved perceptual matching and drawing reproduction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       E. Preserved single-word repetition",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       F. Preserved ability to read aloud and write to dictation orthographically regular words",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       II. Supportive diagnostic features",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       A. Speech and language",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       1. Press of speech",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       2. Idiosyncratic word usage",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       3. Absence of phonemic paraphasias",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       4. Surface dyslexia and dysgraphia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       5. Preserved calculation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       B. Behavior",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       1. Loss of sympathy and empathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       2. Narrowed preoccupations",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       3. Parsimony",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       C. Physical signs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       1. Absent or late primitive reflexes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       2. Akinesia, rigidity, and tremor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       D. Investigations",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       E. Neuropsychology",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       1. Profound semantic loss, manifest in failure of word comprehension and naming and/or face and object recognition",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       2. Preserved phonology and syntax, and elementary perceptual processing, spatial skills, and day-to-day memorizing",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       F. Electroencephalography: normal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       G. Brain imaging (structural and/or functional): predominant anterior temporal abnormality (symmetric or asymmetric)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology 1998; 51:1546. Copyright &copy; 1998 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_61_4061=[""].join("\n");
var outline_f3_61_4061=null;
var title_f3_61_4062="Pleural fluid triglycerides in chylothorax";
var content_f3_61_4062=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F86646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F86646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 593px\">",
"   <div class=\"ttl\">",
"    Pleural fluid triglyceride values in chylothorax",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 573px; height: 425px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pleural fluid total triglyceride values in 74 patients with chylothorax. Boxes show interquartile ranges, and error bars represent highest and lowest values. The mean &plusmn; SD total triglyceride level was 728 &plusmn; 797 mg/dL (median, 483.5 mg/dL; interquartile range, 200 to 936 mg/dL).",
"    <div class=\"footnotes\">",
"     SI conversion factor: To convert total triglyceride values to mmol/L, multiply by 0.0113.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Maldonado F, Hawkins FJ, Daniels CE, et al. Pleural fluid characteristics of chylothorax. Mayo Clin Proc 2009; 84:129. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_61_4062=[""].join("\n");
var outline_f3_61_4062=null;
var title_f3_61_4063="Primary graft dysfunction";
var content_f3_61_4063=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary lung graft dysfunction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 265px; height: 605px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_61_4063=[""].join("\n");
var outline_f3_61_4063=null;
